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The AGC kinases comprise approximately 10% of mammalian kinases, and are broadly 
involved in regulating metabolism, survival and differentiation1. While much is known about 
S6 Kinase and Akt, the precise downstream targets and functions of other enzymes in this 
family have yet to be determined.  Serum- and glucocorticoid-regulated kinase 1 (SGK1) is 
an AGC kinase that plays a role in regulating membrane sodium channel expression in renal 
tubular cells in response to increases in serum osmolarity in an mTORC2-dependent 
manner2. We hypothesized that SGK1 might represent a novel mTORC2-depednent 
downstream regulator of T cell differentiation and function. Here we show that SGK1 is a 
critical regulator of CD4+ effector differentiation into Th1 and Th2 subsets. Specifically, 
upon activation by mTORC2, SGK1 promotes Th2 differentiation by negatively regulating 
the NEDD4-2 E3 ligase mediated destruction of JunB. Simultaneously, SGK1 represses the 
production of IFN-γ by controlling the expression of the long isoform of TCF-1.  
Consistent with these functions, mice in which SGK1 has been selectively deleted in T cells 
fail to generate a robust Th2 response and are resistant to experimentally induced asthma.  
Likewise, such mice generate robust levels of IFN-γ in response to vaccines and more 
readily reject tumors.  Loss of SGK1 in CD8+ T cells leads to inappropriate expression of 
memory markers such as CD127 and eomesodermin on effector cells, and subsequently may 
lead to enhanced memory differentiation. Overall these results reveal a novel role for SGK1 
in promoting a signaling program that simultaneously enhances IL-4 production and inhibits 
IFN-γ expression.  Given the ubiquitous expression of SGK1 in mammalian cells, these 
findings provide novel insight into the ability of AGC kinases to regulate cellular function in 
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CHAPTER 1: Introduction 
 
T lymphocytes—both CD4+ and CD8+ T cells—are the workhorses of the adaptive 
immune response1. One of the hallmarks of adaptive immunity is the exquisite specificity of 
the T cell receptor (TCR) for its cognate antigen. During T cell development, through the 
process of V(D)J recombination, the TCR genetic locus is stochastically rearranged to 
generate a diverse repertoire of antigen receptors that can recognize up to 1x109 different 
pathogens2. Despite the exquisite specificity of the TCR for its cognate antigen, however, 
this interaction does not impart any instructive information to guide T cell differentiation. 
Upon encountering antigen, naïve T cells must differentiate into various distinct lineages 
(Fig 1)3. These subsets possess particular functional capabilities that endow the cell to 
respond to the pathogen; however, recognition of the pathogen alone does not provide 
information about which subset is necessary for a productive immune response. 
 
The two signal model of antigen recognition 
The two signal model of T cell recognition posits that the outcome of antigen recognition 
(signal 1) is determined by a second signal derived from an antigen presenting cell (APC)4. 
First proposed by Lafferty & Cunningham5 and Bretscher & Cohn6 in the 1970s, the two 
signal model has evolved along with our understanding of the inflammatory mileu and 
metabolic demands of the adaptive immune response. Signal 2 is the actually the sum of 
multiple inputs: both costimulatory and inhibitory signals, cytokine receptor signals, 
environmental cues, and the availability of nutrients7,8. Thus, T cells must coordinate 
multiple inputs to produce a singular output in order to dictate the outcome of antigen 
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recognition. There is a growing appreciation that this process of signal integration is carried 
out by an evolutionarily conserved serine-threonine kinase called mTOR8,9. 
 
The mechanistic target of rapamycin (mTOR) is a central node in an intracellular signaling 
network that receives multiple inputs from cytokines, costimulatory receptors, 
environmental cues, and metabolic demands10. While it has long been appreciated that 
cytokines influence the immune response, there is an emerging paradigm that cellular 
metabolism is inextricably linked to T cell differentiation11. In this model, mTOR is proving 
to be a vital link between metabolism and immune function. Beyond T lymphocytes, mTOR 
regulates multiple types of immune cells, including neutrophils, mast cells, natural killer cells, 
γδ T cells, macrophages, dendritic cells (DCs), and B cells8,12,13. This dissertation will focus 
on the role of mTOR in guiding fate decisions of both CD4+ and CD8+ T lymphocytes.  
 
mTOR signaling 
First discovered in yeast14,15, the mTOR kinase is the core catalytic component of a signaling 
complex that plays a role in regulating cell growth, metabolism and survival16. The C-
terminus of mTOR is composed of two N-terminal HEAT (huntington, elongation factor 3, 
subunit of PP2A, and TOR) domains, which mediate protein-protein interactions (Fig 2). 
The FRB domain is the binding site for the 12 kDa FK506-binding protein (FKBP12), 
which binds the macrolide drug rapamycin. Originally discovered in soil samples from Easter 
Island (the local name being Rapa nui), rapamycin was found to be a poor antibiotic17. 
However, this macrolide drug was found to have potent immunosuppressive properties.  
Numerous analogs of rapamycin have since been developed, but the most potent inhibitors 
of mTOR are those drugs that bind to the kinase domain. The mTOR serine-threonine 
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kinase catalytic domain lies C-terminal to the FRB site.  mTOR kinase inhibitors, such as 
pp242 and Torin1, function as ATP-competitive inhibitors at the catalytic domain to 
specifically and potently inhibit mTOR signaling18,19. 
 
Yeast express two TOR genes which play a critical role in coupling the availability of 
nutrients with cell growth only under favorable environmental conditions20. Interestingly, in 
higher organisms TOR exists as one gene product which can signal via two distinct 
complexes, TORC1 and TORC2 (Fig 3)10. In mammalian cells, TORC1 is responsible for 
regulating cell growth, metabolism, and cap-dependent protein translation, while TORC2 
regulates cellular functions such as actin reorganization and survival21. In some mammalian 
cell lineages such as lymphocytes of the immune system, the nutrient-sensing TOR pathway 
has been co-opted to perform highly specialized functions, such as the integration of 
multiple signals in the immune microenvironment to direct cellular differentiation. Various 
inputs in the form of nutrients, costimulation, and cytokines feed into the mTOR pathway. 
In a coordinated fashion, these cell extrinsic differentiation cues are integrated by mTOR, 
which in turn activates diverse downstream pathways to determine cell fate.  
 
mTORC1 signaling 
The mTORC1 signaling complex is formed when mTOR associates with a particular set of 
adaptor proteins (Fig 2). Some of these accessory proteins act as scaffolds to promote 
binding of other proteins, while others function as key regulators of the signaling complex. 
The mTORC1 complex is composed of regulatory-associated protein of mTOR (raptor), 
mammalian lethal with Sec13 protein 8 (mLST8), and the proline-rich Akt substrate 40 kDa 
(PRAS40)22-24. mTORC1 is activated by its association with the small GTPase Rheb (ras 
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homologue enriched in brain), which itself is negatively regulated by the tuberous sclerosis 
complex 1/2 (TSC1/2)25,26. The adaptor protein and DEP-domain-containing mTOR-
interacting protein (Deptor) can also negatively regulate mTORC1 activity27.  
 
Activation of mTORC1 is regulated by upstream signals, including oxygen tension, the 
availability of nutrients, and the overall energy status of the cell (Fig 3). A high AMP/ATP 
ratio (indicating low energy status) activates AMPK, which in turn activates TSC1/2, leading 
to repression of mTORC128,29. Hypoxia also activates AMPK and ultimately leads to 
decreased mTORC1 activity30. By contrast, the availability of essential amino acids leads to 
activation of mTORC1 through activation of the heterotrimeric GTPases RagA-D, which 
interact with Raptor to provide a docking site for mTORC1 at lysosomal membranes31-33. 
Additionally, mTORC1 activity can be induced via cytokine and growth factor induced 
signaling, which is mediated via phosphoinositide 3-kinase (PI-3K) activation. 
 
Upon activation of mTORC1, mTOR  phosphorylates p70-S6 Kinase, leading to the 
phosphorylation of ribosomal S6 protein which allows for enhanced protein translation34. 
Phosphorylation of 4E-BP1 by mTOR releases eIF4E to participate in cap-dependent 
translation by recruiting eIF4G to the 5’ mRNA cap35. Along with increasing protein 
translation, mTORC1 activity also upregulates gene expression programs necessary for 
glucose and lipid metabolism, mitochondria biogenesis and inhibition of autophagy.  
 
mTORC2 signaling 
mTORC2 is composed of mLST8 in addition to the scaffolding protein rapamycin-
independent companion of TOR (rictor), mammalian stress-activated 
 4 
protein kinase interacting protein (mSIN1), and the protein observed with rictor (Protor) 
(Fig 2)22,23.  Recently, two studies have described positive and negative upstream regulators 
of mTORC2 activity. While physical association of mTORC2 with ribosomes in a PI-3K 
dependent manner promotes mTORC2 kinase activity, ER stress can inhibit mTORC2 
activity via glycogen synthase kinase 3β (GSK3β) (Fig 3) 36,37. Activation of mTORC2 leads 
to phosphorylation and activation of a number of downstream AGC kinases including Akt, 
protein kinase C (PKC), and serum- and glucocorticoid- regulated kinase 1 (SGK1)38-40.  
 
AGC Kinase signaling 
AGC kinases—named for their homology to cAMP dependent protein kinase A, cGMP 
dependent kinase G, and protein kinase C—are a family of highly conserved 
serine/threonine kinases41. S6 Kinase, Akt and SGK1 are all AGC kinases in the mTOR 
signaling network that have similar sequence motifs and domain structures. Each of these 
AGC kinases contains two regulatory domains: an activation or T-loop domain, and a 
hydrophobic motif41. Akt contains two additional regulatory domains, which include a turn 
motif and a pleckstrin homology (PH) domain. Constitutive phosphorylation of the turn 
motif occurs soon after Akt is synthesized, and this is thought to stabilize the protein and 
protect the hydrophobic motif from dephosphorylation39. The PH domain of Akt interacts 
with high affinity with hydrolyzed phospholipids, including phosphatidylinositol-3,4,5-
triphosphate (PIP3) and its breakdown product phosphatidylinositol-3,4-bishosphate 
(PIP2)42. This interaction recruits Akt to the plasma membrane of the cell and induces a 
conformational change in the protein so it can be phosphorylated at its T loop domain by 3-
phosphoinositide-dependent kinase 1 (PDK1)43,44 . This phosphorylation at threonine 308 
only partially activates Akt, but phosphorylation of the hydrophobic motif is necessary for 
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full activation. The hydrophobic motif of both Akt and SGK1 are phosphorylated by 
mTORC2 at serine 473 and 422, respectively. Like Akt, SGK1 is also phosphorylated by 
PDK1 at its T loop domain by PDK1.   
 
While Akt and SGK1 are highly homologous, there are key differences in the way these 
enzymes are activated. In addition, Akt and SGK1 have partially overlapping but 
nonredundant functions and substrate specificities downstream of mTORC2. For example, 
the N-myc downregulated gene 1 (NDRG1) and the ubiquitin E3 ligase neural precursor cell 
expressed, developmentally down-regulated 4-2 (NEDD4-2) are both exclusive target of 
SGK144,45. Since relatively more is known about Akt, there have been over 130 substrates 
identified for this AGC kinase41. On the other hand, Akt and SGK1 share some targets. For 
example, the forkhead box transcription factors (FOXO) are shared substrates of both 
SGK1 and Akt46. For example, Akt seems to favor phosphorylation of Foxo1 at serine 253, 
while SGK1 favors serine 31546. On the other hand, both Akt and SGK1 readily 
phosphorylate threonine 32 in Foxo146. The different substrate specificities of Akt and 
SGK1 thus impart a unique functional repertoire to these AGC kinases downstream of 
mTORC2. 
 
mTOR in the immune system 
The immune microenvironment plays a critical role in directing the outcome of antigen 
recognition. By integrating multiple signals from the immune microenvironment, mTOR 
exists at the interface between extracellular signals and T cell fate decisions. Both mTORC1 
and mTORC2 are activated downstream of TCR signaling, and the magnitude of activation 
is correlated with the duration of TCR stimulation and the dose of antigen47. Costimulatory 
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signaling from CD28 feeds into the mTOR pathway by activating PI-3K and Akt48,49. By 
contrast, negative regulators of TCR signaling, such as the programmed cell death protein 1 
(PD1), inhibit mTOR signaling50.  
 
Given its central role in T cell metabolism and differentiation, deletion of mTOR at the 
double positive stage of T cell development using CD4-Cre does not disrupt T cell 
homeostasis47. Mice lacking mTOR have a normal compartment of naïve CD4+ and CD8+ 
T cells, as well as T regulatory (Treg) cells. Interestingly, loss of mTOR in CD4+ T cells 
results in an inability to differentiate to any of the T helper effector lineages (Th1, Th2, or 
Th17)47. Instead, cells lacking mTOR adopt a default regulatory phenotype47. The mTOR 
deficient T cells display constitutively high expression of FoxP3 and hyperphosphorylation 
of Smad3, even in the absence of exogenous TGF-β47. 
 
Subsequently we have employed genetic models to study the consequences of selectively 
ablating mTORC1 or mTORC2 activity in T cells51. To generate an mTORC1 knockout, we 
deleted the small GTPase Rheb in CD4 T cells (T-Rheb-/-)51. To generate an mTORC2 
knockout, we deleted the adaptor protein Rictor in CD4 T cells (T-Rictor-/-)51. We found that 
T-Rheb-/- mice could not adopt a Th1 or Th17 phenotype 51. In an experimental 
autoimmune encephalomyelitis model of disease (EAE), T-Rheb-/- mice were protected from 
the classical Th1/Th17-mediated autoimmune paralysis, but instead developed a Th2-
mediated autoimmune cerebellar ataxia (atypical EAE). By contrast, T-Rictor-/- mice have 
defective Th2 differentiation, characterized by decreased IL4 production and diminished 
STAT6 phosphorylation51.  Interestingly, deletion of either mTORC1 or mTORC2 activity 
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does not lead to an increase in Treg differentiation, suggesting that both mTOR complexes 
must be inhibited in order to promote a regulatory cell fate51.  
 
In CD8+ T cells, several studies have shown that mTOR dictates effector versus memory 
differentiation52-54. Unpublished work from our laboratory using genetic mouse models 
suggests that mTORC1 is necessary for effector differentiation, while mTORC2 is necessary 
for memory differentiation. Studies using rapamycin have previously shown that mTOR 
inhibition can lead to both enhanced effector and memory differentiation52. In a mouse 
model of Lymphocytic Choriomeningitis Virus (LCMV), rapamycin was shown to increase 
the number of virus-specific CD8 T cells by promoting survival of memory T cells during 
the contraction phase of the immune response52. However, since prolonged exposure to 
rapamycin can inhibit both mTORC1 and mTORC2, it is unclear from these studies what is 
the mechanism underlying enhanced effector and memory generation. 
 
There is still much work to be done in order to understand how signaling events 
downstream of mTOR regulate T cell differentiation and metabolism. We propose that 
differential signaling via mTORC1 and mTORC2 leads to the upregulation of distinct gene 
expression programs characteristic of a particular immune and metabolic phenotype. Our 
strategy has been to employ mouse genetic models to elucidate the role of each TOR 
complex in driving metabolic and fate decisions. More recently, we have become interested 
in kinases downstream of mTOR that are responsible for activating transcriptional networks 
to influence T cell fate.  
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The remainder of this dissertation will focus on one such protein that is activated 
downstream of mTORC2 called the serum- and glucocorticoid regulated kinase 1 (SGK1). 
Until recently, very little was known about the role of SGK1 in the immune system. The 
focus of this work will be on the role of SGK1 in CD4+ T cell differentiation into Th1 and 
Th2 subsets (Chapter 2) and the role of SGK1 in CD8+ T cell effector and memory 
differentiation (Chapter 3).  
 
Figure Legends 
Figure 1. CD4+ and CD8+ T cell differentiation. Upon TCR stimulation in the presence 
of costimulation, naïve CD4+ or CD8+ T cells differentiate into distinct various lineages. 
For CD4+ T cells, cytokines such as IFN-γ and IL-12 direct differentiation toward a Th1 
phenotype, which is characterized by the lineage-spefici transcription factor Tbet and 
STAT4. Th2 differentiation occurs in the presence of IL-4, and this lineage is characterized 
by the GATA-3 and STAT6 transcription factors. Cytokines like IL-6 and TGF-β promote 
Th17 development, with expression of ROR-γT and STAT3. If CD4+ T cells are stimulated 
in the presence of TGF-β alone, however, these cells adopt a regulatory T cell fate (Treg), 
which is characterized by FoxP3 expression. For CD8+ T cells, differentiation can result in 
at least two distinct subsets: effector (TEFF) and memory (TMEM) cells. How these 
populations arise is controversial, but they can be distinguished phenotypically based on cell 
surface markers and transcription factor expression. While TEFF are KLRG1HI, CD127low 
and express the transcription factor Tbet, TMEM cells are KLRG1low, CD127 high and 




Figure 2. Structure of mTOR, TORC1 and TORC2 signaling complexes. (A) mTOR 
is an evolutionarily conserved 289 kDA serine-threonine protein kinase that is composed of 
two N-terminal HEAT (huntington, elongation factor 3, subunit of PP2A, and TOR) 
domains, which mediate protein-protein interactions, adjacent to a FRAP, ATM, and 
TRRAP (FAT) domain. The FRB domain is where the small 12 kDa FK506-binding protein 
(FKBP12) bound to the macrolide drug rapamycin binds to mTOR to inhibit its activity. 
The mTOR Kinase catalytic domain lies C-terminal to the FRB site, and this is where 
mTOR kinase inhibitors bind. The Carboxy FAT domain maintains structural integrity of 
this large protein kinase.  (B) mTOR associates with two distinct sets of adapter proteins to 
form two intracellular signaling complexes with unique substrate specificity. The TORC1 
signaling complex is composed of the regulatory-associated protein of mTOR (raptor) and 
mammalian lethal with Sec13 protein 8 (mLST8), which are both adapter proteins that 
mediate protein-protein interactions via their WD-40 domains. The proline-rich Akt 
substrate 40 kDa (PRAS40) and DEP-domain-containing mTOR-interacting protein 
(Deptor) inhibit mTORC1 activity. The mTORC2 complex can also associate with Deptor 
and mLST8, but this complex is distinguished by the adapter protein raptor-independent 
companion of TOR (rictor) and protein observed with rictor (protor). Another unique 
component of mTORC2 is mSin1, which contains a plekstrin homology domain that is 
thought to target TORC2 to the membrane, where it can activate myristolated Akt. 
 
Figure 3. Overview of the mTOR signaling pathway. The mammalian target of 
rapamycin (mTOR) associates with distinct sets of adaptor proteins to form the mTORC1 
and mTORC2 signaling complexes. Growth factors, cytokines and comstimulation activate 
mTORC1 via PI3K activation, while amino acids activate the Ragulator complex (RagA-D). 
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Oxygen and energy availability control mTORC1 via the regulation of AMPK. The canonical 
downstream targets of mTORC1 include 4E-BP1 and S6 Kinase. mTORC2 is activated by 
its association with ribosomes and inhibited by endoplasmic reticulum (ER) stress. SGK1, 
PKC, and Akt are activated downstream of mTORC2, but Akt also negatively regulates 




1 Murphy, K., Travers, P., Walport, M. & Janeway, C. Janeway's immunobiology. 8th edn,  
(Garland Science, 2012). 
2 Schatz, D. G. & Ji, Y. Recombination centres and the orchestration of V(D)J 
recombination. Nat Rev Immunol 11, 251-263, doi:10.1038/nri2941 
nri2941 [pii] (2011). 
3 Yamane, H. & Paul, W. E. Early signaling events that underlie fate decisions of naive 
CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev 252, 12-23, 
doi:10.1111/imr.12032 (2013). 
4 Bretscher, P. A. A two-step, two-signal model for the primary activation of precursor 
helper T cells. Proc Natl Acad Sci U S A 96, 185-190 (1999). 
5 Lafferty, K. J. & Cunningham, A. J. A new analysis of allogeneic interactions. Aust J 
Exp Biol Med Sci 53, 27-42 (1975). 
6 Bretscher, P. & Cohn, M. A theory of self-nonself discrimination. Science 169, 1042-
1049 (1970). 
 11 
7 Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and 
B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068, 
doi:S0092-8674(05)80055-8 [pii] (1992). 
8 Powell, J. D., Pollizzi, K. N., Heikamp, E. B. & Horton, M. R. Regulation of immune 
responses by mTOR. Annu Rev Immunol 30, 39-68, doi:10.1146/annurev-immunol-
020711-075024 (2012). 
9 Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev 
Immunol 12, 325-338, doi:10.1038/nri3198 
nri3198 [pii] (2012). 
10 Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to 
cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35, doi:nrm3025 [pii] 
10.1038/nrm3025 (2011). 
11 Gerriets, V. A. & Rathmell, J. C. Metabolic pathways in T cell fate and function. 
Trends Immunol 33, 168-173, doi:10.1016/j.it.2012.01.010 
S1471-4906(12)00019-1 [pii] (2012). 
12 Weichhart, T. & Saemann, M. D. The multiple facets of mTOR in immunity. Trends 
Immunol 30, 218-226, doi:10.1016/j.it.2009.02.002 
S1471-4906(09)00062-3 [pii] (2009). 
13 Thomson, A. W., Turnquist, H. R. & Raimondi, G. Immunoregulatory functions of 
mTOR inhibition. Nat Rev Immunol 9, 324-337, doi:10.1038/nri2546 
nri2546 [pii] (2009). 
14 Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor 
complex. Nature 369, 756-758, doi:10.1038/369756a0 (1994). 
 12 
15 Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. 
RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent 
fashion and is homologous to yeast TORs. Cell 78, 35-43, doi:0092-8674(94)90570-3 
[pii] (1994). 
16 Laplante, M. & Sabatini, D. M. mTOR Signaling. Cold Spring Harb Perspect Biol 4, 
doi:10.1101/cshperspect.a011593 
a011593 [pii] 
cshperspect.a011593 [pii] (2012). 
17 Vezina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal 
antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active 
principle. J Antibiot (Tokyo) 28, 721-726 (1975). 
18 Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor 
reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284, 8023-8032, 
doi:10.1074/jbc.M900301200 
M900301200 [pii] (2009). 
19 Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant 
outputs of mTORC1 and mTORC2. PLoS Biol 7, e38, doi:08-PLBI-RA-4959 [pii] 
10.1371/journal.pbio.1000038 (2009). 
20 Dann, S. G. & Thomas, G. The amino acid sensitive TOR pathway from yeast to 
mammals. FEBS Lett 580, 2821-2829, doi:S0014-5793(06)00508-4 [pii] 
10.1016/j.febslet.2006.04.068 (2006). 
21 Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 
149, 274-293, doi:10.1016/j.cell.2012.03.017 
S0092-8674(12)00351-0 [pii] (2012). 
 13 
22 Laplante, M. & Sabatini, D. M. mTOR signaling at a glance. J Cell Sci 122, 3589-3594, 
doi:10.1242/jcs.051011 
122/20/3589 [pii] (2009). 
23 Yecies, J. L. & Manning, B. D. Transcriptional control of cellular metabolism by 
mTOR signaling. Cancer Res 71, 2815-2820, doi:0008-5472.CAN-10-4158 [pii] 
10.1158/0008-5472.CAN-10-4158 (2011). 
24 Wang, L., Harris, T. E., Roth, R. A. & Lawrence, J. C., Jr. PRAS40 regulates 
mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J 
Biol Chem 282, 20036-20044, doi:M702376200 [pii] 
10.1074/jbc.M702376200 (2007). 
25 Yamagata, K. et al. rheb, a growth factor- and synaptic activity-regulated gene, 
encodes a novel Ras-related protein. J Biol Chem 269, 16333-16339 (1994). 
26 Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor 
proteins. Nat Cell Biol 5, 578-581, doi:10.1038/ncb999 
ncb999 [pii] (2003). 
27 Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in 
multiple myeloma cells and required for their survival. Cell 137, 873-886, doi:S0092-
8674(09)00389-4 [pii] 
10.1016/j.cell.2009.03.046 (2009). 
28 Sengupta, S., Peterson, T. R. & Sabatini, D. M. Regulation of the mTOR complex 1 




29 Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic 
checkpoint. Mol Cell 30, 214-226, doi:S1097-2765(08)00169-X [pii] 
10.1016/j.molcel.2008.03.003 (2008). 
30 Schneider, A., Younis, R. H. & Gutkind, J. S. Hypoxia-induced energy stress inhibits 
the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck 
squamous cell carcinoma. Neoplasia 10, 1295-1302 (2008). 
31 Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1. Science 320, 1496-1501, doi:1157535 [pii] 
10.1126/science.1157535 (2008). 
32 Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. & Guan, K. L. Regulation of 
TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10, 935-945, doi:ncb1753 
[pii] 
10.1038/ncb1753 (2008). 
33 Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface 
and is necessary for its activation by amino acids. Cell 141, 290-303, doi:S0092-
8674(10)00177-7 [pii] 
10.1016/j.cell.2010.02.024 (2010). 
34 Holz, M. K. & Blenis, J. Identification of S6 kinase 1 as a novel mammalian target of 
rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280, 26089-26093, 
doi:M504045200 [pii] 
10.1074/jbc.M504045200 (2005). 
35 Holz, M. K., Ballif, B. A., Gygi, S. P. & Blenis, J. mTOR and S6K1 mediate assembly 
of the translation preinitiation complex through dynamic protein interchange and 
ordered phosphorylation events. Cell 123, 569-580, doi:S0092-8674(05)01157-8 [pii] 
 15 
10.1016/j.cell.2005.10.024 (2005). 
36 Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by 
association with the ribosome. Cell 144, 757-768, doi:S0092-8674(11)00128-0 [pii] 
10.1016/j.cell.2011.02.014 (2011). 
37 Chen, C. H. et al. ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-
mediated phosphorylation of rictor. Sci Signal 4, ra10, doi:10.1126/scisignal.2001731 
4/161/ra10 [pii] (2011). 
38 Guertin, D. A. et al. Ablation in mice of the mTORC components raptor, rictor, or 
mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and 
PKCalpha, but not S6K1. Dev Cell 11, 859-871, doi:S1534-5807(06)00459-X [pii] 
10.1016/j.devcel.2006.10.007 (2006). 
39 Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. & Guan, K. L. Essential function of 
TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. 
EMBO J 27, 1919-1931, doi:10.1038/emboj.2008.119 
emboj2008119 [pii] (2008). 
40 Garcia-Martinez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2) controls 
hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-
induced protein kinase 1 (SGK1). Biochem J 416, 375-385, doi:BJ20081668 [pii] 
10.1042/BJ20081668 (2008). 
41 Pearce, L. R., Komander, D. & Alessi, D. R. The nuts and bolts of AGC protein 
kinases. Nat Rev Mol Cell Biol 11, 9-22, doi:10.1038/nrm2822 
nrm2822 [pii] (2010). 
 16 
42 Kohn, A. D., Takeuchi, F. & Roth, R. A. Akt, a pleckstrin homology domain 
containing kinase, is activated primarily by phosphorylation. J Biol Chem 271, 21920-
21926 (1996). 
43 Currie, R. A. et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the 
activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 
337 ( Pt 3), 575-583 (1999). 
44 Murray, J. T. et al. Exploitation of KESTREL to identify NDRG family members as 
physiological substrates for SGK1 and GSK3. Biochem J 384, 477-488, 
doi:BJ20041057 [pii] 
10.1042/BJ20041057 (2004). 
45 Debonneville, C. et al. Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial 
Na(+) channel cell surface expression. EMBO J 20, 7052-7059, 
doi:10.1093/emboj/20.24.7052 (2001). 
46 Brunet, A. et al. Protein kinase SGK mediates survival signals by phosphorylating the 
forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21, 952-965, 
doi:10.1128/MCB.21.3.952-965.2001 (2001). 
47 Delgoffe, G. M. et al. The mTOR kinase differentially regulates effector and 
regulatory T cell lineage commitment. Immunity 30, 832-844, doi:S1074-
7613(09)00237-4 [pii] 
10.1016/j.immuni.2009.04.014 (2009). 
48 Colombetti, S., Basso, V., Mueller, D. L. & Mondino, A. Prolonged TCR/CD28 
engagement drives IL-2-independent T cell clonal expansion through signaling 
mediated by the mammalian target of rapamycin. J Immunol 176, 2730-2738, 
doi:176/5/2730 [pii] (2006). 
 17 
49 Zheng, Y. et al. A role for mammalian target of rapamycin in regulating T cell 
activation versus anergy. J Immunol 178, 2163-2170, doi:178/4/2163 [pii] (2007). 
50 Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function 
of induced regulatory T cells. J Exp Med 206, 3015-3029, doi:10.1084/jem.20090847 
jem.20090847 [pii] (2009). 
51 Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells 
through the selective activation of signaling by mTORC1 and mTORC2. Nat 
Immunol 12, 295-303, doi:ni.2005 [pii] 
10.1038/ni.2005 (2011). 
52 Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-
112, doi:nature08155 [pii] 
10.1038/nature08155 (2009). 
53 Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid 
metabolism. Nature 460, 103-107, doi:nature08097 [pii] 
10.1038/nature08097 (2009). 
54 Rao, R. R., Li, Q., Odunsi, K. & Shrikant, P. A. The mTOR kinase determines 
effector versus memory CD8+ T cell fate by regulating the expression of 


































































































CHAPTER 2: The AGC kinase serum- and glucocorticoid-regulated kinase 1 (SGK1) 
regulates TH1 and TH2 differentiation downstream of mTORC2 
 
Introduction 
AGC kinases are serine/threonine protein kinases that are broadly involved in 
regulating numerous aspects of cell physiology, including growth, survival and metabolism1.  
The serum- and glucocorticoid-regulated kinase 1 (SGK1) is an AGC kinase that is activated 
by sequential phosphorylation of two highly conserved regulatory motifs. The T-loop 
domain is phosphorylated at threonine 256 by the kinase PDK1 (ref. 2), and the 
hydrophobic motif is phosphorylated at serine 422 by mTORC2 (refs. 3,4). Compared to 
other AGC kinases that are also downstream of mTOR, such as Akt and S6 kinase, relatively 
little is known about SGK1. Downstream targets of SGK1 include E3 ubiquitin ligases such 
as NEDD4-2 (refs. 5,6), transcription factors such as Foxo7,8, and other kinases like GSK-
3b9. In the kidney, SGK1 phosphorylates and inhibits NEDD4-2 to prevent degradation of 
the epithelial Na+ channel, thus allowing sodium to be reclaimed in the urine when serum 
concentrations of sodium are low5,10,11. Recently, it has been shown that SGK1 mRNA is 
upregulated by sodium in lymphocytes, and that mice that are fed a high salt diet develop 
more severe TH17-mediated autoimmune encephalomyelitis12,13. Loss of SGK1 in T cells 
leads to a selective defect in pathogenic TH17 differentiation, due to decreased expression of 
the interleukin 23 (IL-23) receptor12. The role of SGK1 in other T cell lineages, however, has 
yet to be determined. 
 
We became interested in SGK1 because it is a downstream target of mTOR, which 
serves as a critical node in a highly conserved signaling pathway that integrates multiple 
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inputs from the environment14,15. In the immune system, mTOR integrates various signals, 
such as cytokines and costimulatory molecules, to influence T cell differentiation15. mTOR 
can associate with two distinct protein complexes (mTORC1 and mTORC2) to drive the 
selective differentiation of CD4+ T cells. Genetic deletion of mTOR in CD4+ T cells has 
shown that loss of both mTORC1 and mTORC2 signaling results in a default T regulatory 
(Treg) phenotype upon T cell activation16,17. Loss of either mTORC1 or mTORC2 leads to 
selective deficits in distinct T cell lineages. For example, genetic deletion of the mTORC2 
adapter protein Rictor in CD4+ T cells results in defective TH2 differentiation, characterized 
by an inability to produce IL-4 (refs. 18,19). Despite the critical role of mTOR in regulating 
T effector and Treg cell differentiation, the precise downstream targets of mTOR that 
control differentiation into distinct helper T cell subsets have yet to be elucidated.   
 
Because SGK1 is a downstream target of mTORC2, we hypothesized that it might 
be involved in mTORC2 regulation of TH2 lineage commitment.  To this end, we generated 
mice in which SGK1 was selectively deleted in T cells by crossing Sgk1fl/fl mice11 with Cd4-
Cre expressing mice (hereafter referred to as T-Sgk1–/– mice). We show that loss of SGK1 
led to decreased production of IL-4 and inappropriate release of interferon-g (IFN-g) under 
TH2 polarizing conditions in vitro. In a mouse model of allergic asthma, we found that loss of 
SGK1 resulted in diminished TH2 responses and protection against disease. Mechanistically, 
we show that SGK1 promoted TH2 differentiation by preventing ubiquitination and 
destruction of the transcription factor JunB by NEDD4-2 and its adaptor protein Ndfip. 
Alternatively, we found that T-Sgk1–/– mice produced increased amounts of IFN-g under 
TH1 polarizing conditions in vivo, which was associated with both stronger anti-tumor and 
anti-viral immune responses. The ability of SGK1 to inhibit TH1 differentiation was 
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mediated in part by its ability to regulate the expression of the long isoform of TCF-1 via b-
catenin and GSK-3b. Overall, our findings define distinct signaling pathways downstream of 




Mice. Mice were kept in accordance with guidelines of the Johns Hopkins University 
Institutional Animal Care and Use Committee. Mice with loxP-flanked Sgk1 alleles were 
described previously11, and mice with loxP-flanked Rictor alleles were provided by M. 
Magnuson40. C57BL/6, Cd4-Cre and OT-II mice were obtained from Jackson Laboratories 
and bred to Thy-1.1 backgrounds. 5C.C7 mice were from Taconic Farms. 
 
Antibodies and reagents. The following antibodies for flow cytometry were from BD 
Biosciences: anti-B220 (RA3-6B2), anti-CD3 (2C11), anti-CD4 (RM4-5), anti-CD8 (Ly-3), 
anti-CD25 (PC61), anti-CD44 (IM7), anti-CD124 (mIL4R-M1), anti-IFN-g (XMG1.2), anti-
IL-17a (TC11-18H10), and anti-human CD8 (RPA-T8). Anti-CD62L (MEL-14), anti-IL-13 
(eBio13A), anti-IL-5 (TRFK5), anti-T-bet (eBio4B10) and anti-Foxp3 (FJK-16s) were from 
eBioscience.  
The following antibodies for immunoblotting were from Cell Signaling Technologies: 
Antibody to Rictor (2140), NDRG1 phosphorylated at Thr346 (5482), total NDRG1 (9408), 
antibody to Akt phosphorylated at S473 (4060), pan-Akt (4685), NEDD4-2 phosphorylated 
at Ser342 (4080), total NEDD4-2 (4013), TCF-1 (2206), antibody to b-catenin (9562), 
antibody to phosphorylated b-catenin (9561), antibody to phosphorylated STAT6 (9361). 
Anti-T-bet (4B10) and anti-GATA-3 (TWAJ) were from eBioscience. Anti-JunB (210) was 
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from Santa Cruz Biotechnology. Anti-ubiquitin was and actin were from Sigma. MG132 was 
from Sigma, PP242 was from Calbiochem, and CFSE was from Invitrogen. 
  
T cell stimulation and polarization. CD4+ T cells were purified by negative selection 
using a CD4+ isolation kit and MACS Cell Separation (Miltenyi Biotec). For polarizing 
experiments, T cells were stimulated with irradiated autologous APCs or with plate-bound 
anti-CD3 and soluble anti-CD28. For APC-free stimulations, flat-bottomed plates were 
coated with anti-CD3 (3 mg/ml) diluted in PBS, and soluble anti-CD28 (2 mg/ml) was 
added to the cultures. For stimulation with APCs, T cells were cultured with irradiated APCs 
and anti-CD3 (1 mg/ml), followed by rest and expansion for 5 days. For rechallenge, live 
cells were harvested by Ficoll gradient, washed, and then stimulated with plate-bound anti-
CD3 (1 mg/ml) and soluble anti-CD28 (2 mg/ml). Polarizing conditions were as follows: 
TH0, anti-IL-4 (5 mg/ml) and anti-IFN-g (5 mg/ml), with IL-2 (1 ng/ml) during the rest 
period; TH1, IL-12 (5 ng/ml), IFN-g (100 ng/ml) and anti-IL-4 (5 mg/ml), with IL-2 (1 
ng/ml) during the rest period; TH2, IL-4 (10 ng/ml), anti-IL-12 (5 mg/ml) and anti-IFN-g (5 
mg/ml), with IL-2 (1 ng/ml) during the rest period; TH17, IL-6 (30 ng/ml), TGF-β (3 
ng/ml), anti-IFN-g (5 mg/ml), anti-IL-4 (5 mg/ml), and IL-23 (10 ng/ml) during the rest 
period. Stimulatory anti-CD3 (2C11) and anti-CD28 (37.51), as well as neutralizing anti-IFN-
g (XMG1.2) and anti-IL-4 (11B11) were purified from hybridoma supernatants prepared in-





Adoptive transfer. 1 × 106 naïve CD4+ T cells specific for the OVA MHC class II epitope 
(OVA aa329-337) congenically marked with Thy1.1 were transferred intravenously to Thy1.2 
C57BL/6 recipients by retro orbital injection. 1 × 106 pfu Vac-OVA was simultaneously 
administered by either retro orbital injection or intraperitoneal injection. 
 
House Dust Mite Asthma Model. On days 0 and 7, mice were primed by intraperitoneal 
injection of 10 mg of house dust mite (HDM) extract (D. pteronyssinus, Greer Labs) in PBS. 
On days 14 and 21, mice were challenged via inhalation of 50 mg HDM extract per nostril. 
On day 24, mice are sacrificed for analysis. Lymphocytes from bronchoalveolar lavage (BAL) 
and mediastinal lymph nodes were stimulated ex vivo with PMA (phorbol 12-myristate 13-
acetate) and ionomycin for 4 h. Lung lymphocytes were stimulated ex vivo with 30 mg HDM 
extract for 72 h, and supernatant from cultures were analyzed by ELISA. Differential cellular 
analysis of BAL was done via cytospin and Diff-quick staining. For histological analysis, 
lungs were formalin fixed, embedded in paraffin, and stained with hematoxylin and eosin, or 
periodic acid-Schiff (PAS), and scored by previously reported methods41. Peribronchiolar 
and perivascular inflammation was determined by a semi-quantitatively graded scale from 0-
3, where a score of 0 = absent inflammation, 1 = mild, 2 = moderate, 3 = severe. Goblet cell 
hyperplasia was assessed by PAS staining of histologic sections, and was semi-quantitatively 
graded on a scale from 0-3, where a score of 0 = no or rare PAS-positive cells, 1 = less than 
10% PAS-positive cells observed at 10X, 2 = between 10% and 25% PAS-positive cells 
observed at 10X, and 3 = greater than 25% PAS-positive cells observed at 4X. A composite 
score was determined by multiplying the graded score and the percent of airways or vessels 
that exhibited a given pathological finding. All scoring was performed by a pathologist (P. 
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Illei), who was blinded to the identity of the samples, and all slides were examined in a 
random order. 
 
Influenza Model. On day 0, mice were challenged with intranasal influenza strain PR8 
(Charles River) by injecting 600 egg infective dose (EID) per nostril for a final dose of 1200 
EID. On day 8, mice were sacrificed. Lymphocytes from the lung were harvested by gentle 
mechanical and chemical digestion of lung parenchyma with collagenase and DNAse and 
stimulated ex vivo with PMA and ionomycin for 4 h. Experimental samples from groups were 
excluded from the final analysis if flow analysis of T lymphocytes from lungs demonstrated 
more than 70% CD44– and no detectable MHC class I or class II NP tetramer-positive cells, 
suggesting inadequate influenza inoculation.  
 
B16 melanoma model. Mice were injected with 2 × 105 B16-OVA cells intravenously on 
day 0 and lungs were harvested 21 days later. Lung lymphocytes were stimulated ex vivo with 
PMA and ionomycin (Sigma) at a concentration of 50 ng/ml and 500 ng/ml, respectively. 
For survival experiments, mice were injected with 1 × 106 pfu VAC-OVA intraperitoneally 
on day 0, followed by intravenous injection with 2 × 105 B16-OVA cells on day 7. 
 
Ovalbumin (OVA) airway sensitization model. OVA (Sigma-Aldrich) was adsorbed by 
gentle shaking for 30 min onto Imject Alum adjuvant (Pierce) to a final concentration of 250 
mg/ml. Mice were primed by intraperitoneal injection of 50 mg of OVA-Alum in 200 ml. 
On day 7, mice were boosted by the same protocol. On days 15, 16, and 17, mice were 
challenged with intranasal OVA by injecting 25 mg OVA in PBS per nostril. On day 18, 




Intracellular staining. Brefeldin A (GolgiPlug; BD Biosciences) or monensin (GolgiStop; 
BD Biosciences) was used for cytokine staining. Cell were stained for surface antigens, fixed 
and made permeable with either the BD Cytofix/Cytoperm or the eBioscience 
Fixation/Permeabilization kit, then stained for intracellular cytokines. For intracellular 
staining of phosphorylated proteins, cells were fixed with 2.0% formalin and permeabilized 
with methanol. 
 
Flow Cytometric Analysis. Flow cytometric data was acquired using a BD FACS Calibur 
or LSR II, and analyzed using FlowJo7.6 (Tree Star Inc, Ashland, OR). Gates were 
determined by using unstimulated controls or isotype controls where appropriate. 
Cells were sorted using a BD FACS Aria at the Flow Cytometry Core at the Sidney Kimmel 
Comprehensive Cancer Center, JHMI. 
 
Immunoblot analysis. For immunoblot analysis of mTOR substrates, CD4+ T cells were 
stimulated in regular medium with anti-CD3 (1 mg/ml), anti-CD28 (2 mg/ml) and antibody 
to hamster immunoglobulin IgG1 (0.75 mg/ml; G94-56; BD Biosciences). T cells were 
harvested by centrifugation and resuspended in ice-cold lysis buffer (20 mM Tris (pH 7.5), 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM b-glycerolphosphate (glycerol-2-phosphate), 1 mM sodium 
orthovanadate, 1 mM PMSF, 1× protease inhibitors (Roche) and lysed at 4 °C for 30 min. 
Lysates were cleared of debris by high-speed centrifugation. Equal protein mass from each 
condition was mixed with 4× LDS buffer (Invitrogen) and boiled for 10 min. Lysates were 
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then loaded into NuPAGE gels (10% Bis–Tris gels, Invitrogen) and run at 150 V for 90 min. 
Protein was transferred to polyvinylidene fluoride (PVDF) membranes with transfer buffer 
(1× NuPAGE Transfer Buffer (Invitrogen) with 20% methanol) at 30 V for 90 min. 
Membranes were blocked in 5% nonfat dry milk (NFDM) for 60 min, washed briefly with 
Tris-buffered saline (pH=8) + 0.1% Tween-20 (TBST) and probed with primary antibody in 
4% bovine serum albumin in TBST overnight at 4 °C. Membranes were washed with TBST 
three times for 10 min and probed with secondary antibody conjugated to horseradish 
peroxidase (HRP) in NFDM. Membranes were washed 2 times in TBST for 5 min, and then 
once in Tris-buffered saline once for 5 min. Enhanced chemiluminescent plus substrate (GE 
Healthcare) was used to detect HRP-labeled antibodies. Blots were developed using a 
Biospectrum Multispectrum Imaging System and images were acquired and analyzed using 
VisionWorks, LS Image Acquisition and Analysis software (UVP). 
 
Enzyme-linked immunosorbent assay. IL-2, IL-4, IL-5, and IL-13 were analyzed by 
enzyme-linked immunosorbent assay as described by the manufacturer (eBioscience). Total 
serum IgE was measured using the following reagents from BD: anti-mouse IgE capture 
antibody (553413), mouse IgE standard (557080), and anti-mouse IgE biotinylated detection 
antibody (553419). HDM and OVA-specific antibodies were analyzed by enzyme-linked 
immunosorbent assay in Nunc-Immuno plates which had been coated overnight at 4 °C 
with 100 ml HDM (25 mg/ml in PBS) or OVA (20 mg/ml in PBS) and blocked for 1 h at 25 
°C with assay diluent (eBioscience). Wells were washed several times and mouse serum 
samples diluted in assay diluent were added for 2 h or overnight. Wells were washed and 
then biotinylated anti-mouse immunoglobulin IgG1a (553441; BD) or IgG2a (553455; BD) 
diluted to a concentration of 0.5 mg/ml in assay diluent was added for 1 h. Wells were 
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washed and then streptavidin-conjugated HRP (eBioscience) was added for 30 min. Wells 
were washed seven times, and then incubated for 15 min with tetramethylbenzidine 
substrate, or until the reaction approached saturation. Linear regression analysis or 
absorbance levels were used to determine antibody titers or relative differences. 
 
Real-time PCR. RNA was isolated and reverse transcribed into cDNA using the 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) according to the 
manufacturer’s protocol. Primers for short and long isoforms of TCF-1 were from Sigma, 
and primers to detect NEDD4-2 and Ndfip were from Applied Biosystems. Primers used to 
detect TCF-1 long isoforms were the following: 5′-CAATCTGCTCATGCCCTACC-3′ 
(forward) and 5′-GCCTGTGAACTCCTTGCTTC-3′ (reverse). Relative amounts of long 
and short isoforms were quantified using real-time PCR with a SYBR green fluorescent 
probe (Applied Biosystems). Quantitative RT-PCR was performed using a Step One Plus 
Real Time PCR System (Applied Biosystems).  
 
Retroviral transduction.  T cells were stimulated with plate-bound anti-CD3 and soluble 
anti-CD28 (as described above) overnight prior to spinfection with supernatants from 293T 
Phoenix cells. The Phoenix helper-free retroviral ecotropic packaging cell line (Nolan 
Laboratory) was transfected using Lipofectamine 2000 (Invitrogen) with plasmids encoding 
MSCV retrovirus containing full-length TCF-1 and a human CD8 reporter. MSCV 
constructs were provided by J. Sen.  
 
siRNA knockdown. T cells were stimulated with plate-bound anti-CD3 and soluble anti-
CD28 (as described above) for 48 h prior to transfection. ON-TARGET siRNA reagents for 
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scrambled control and NEDD4-2 and Ndfip specific RNA-mediated interference were from 
Dharmacon. Nucleofection reagents were from Lonza.  
 
Statistical analysis. Prism version 5.0 (GraphPad Software) was used to perform statistical 
analyses, including unpaired Student’s t-test, 2-way Analysis of Variance (ANOVA), and 





SGK1 is activated upon antigen recognition in T cells 
 
Sgk1 RNA is expressed in resting naïve T cells  (Supplementary Fig. 1a). We 
wanted to determine whether SGK1 is activated upon T cell stimulation by measuring the 
phosphorylation of the SGK1 substrate N-myc downregulated gene 1 (p-NDRG1 T346)20.  
Activation of T cells led to an increase in SGK1 activity (Fig. 1a). The kinetics of SGK1 
activation paralleled the mTORC2-dependent activation of Akt (p-Akt S473). Next, we 
investigated whether SGK1 activity was modulated by polarizing cytokines upon T cell 
activation. Consistent with a recent report12, SGK1 mRNA was expressed under all 
polarizing conditions in vitro, but expression was highest under TH17 conditions 
(Supplementary Fig. 1b). Interestingly, we found that SGK1 activity was acutely induced to 
a similar degree under all polarizing conditions (Fig. 1b).  
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In light of the role of mTOR in regulating SGK1 activity in HEK293T, MCF-7 and 
HeLa cells3,21, we sought to determine whether SGK1 was also activated in an mTOR-
dependent manner in T cells (Supplementary Fig. 2a). Phosphorylation of NDRG1 
increased upon T cell stimulation, but this effect was abrogated in the presence of the 
mTOR kinase inhibitor PP242 (Fig. 1c)22. Consistent with these results, inhibition of Akt 
phosphorylation (p-Akt S473) was also observed, indicating successful blockade of 
mTORC2 activity23,24,25 (Fig. 1c). Likewise, the deletion of the mTORC2 component Rictor 
mitigated both Akt and SGK1 activation (Fig. 2a, Supplementary Fig. 2b,c). Having 
established that SGK1 signaling is mTORC2-dependent in T cells, we wanted to determine 
if SGK1 might function downstream of mTORC2 to regulate helper T cell differentiation.  
To address this question, mice were generated in which SGK1 was selectively deleted in T 
cells by breeding Sgk1fl/fl mice11 with mice transgenic for Cre under control of the Cd4 
promoter and enhancer regions (T-Sgk1–/– mice) (Supplementary Fig. 1a).  Upon 
stimulation, phosphorylation of NDRG1 was markedly decreased in T-Sgk1–/– CD4+ T cells 
(Fig. 2a).  Alternatively, the selective deletion of SGK1 in T cells did not affect Akt or S6 
phosphorylation (Supplementary Fig. 2b,c). 
 
The role of SGK1 in the maturation of peripheral T cells has never been described. 
Thymic development was essentially not different between wild-type and T-Sgk1–/– mice 
(Supplementary Fig. 3a) and there were no differences in the percent of CD3+, B220+, 
CD4+ and CD8+ cells in the spleen and lymph nodes compared to wild-type mice (Fig. 2b-
e).  Subtle differences in absolute T cell numbers and expression of activation markers were 
observed (Supplementary Fig. 3b-g). Finally there was a slight increase in Foxp3+ T cells in 
the spleens of T-Sgk1–/– mice when compared to wild-type mice (6.23% vs 7.50%) however 
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these differences were not observed in the lymph nodes (Supplementary Fig. 3h). T-Sgk1–
/– CD4+ T cells displayed a slightly reduced rate of proliferation (Fig. 2f). Nevertheless, T-
Sgk1–/– CD4+ T cells produce similar amounts of IL-2 compared to wild-type cells (Fig. 2g). 
Thus, the deletion of SGK1 does not greatly impact the composition of the peripheral T cell 
compartment.  
 
SGK1 regulates TH1 and TH2 differentiation 
 
In light of the ability of mTORC2 to regulate TH2 generation18,19, we wanted to 
determine whether loss of SGK1 affected TH1 and TH2 differentiation.  CD4+ T cells from 
wild-type and T-Sgk1–/– mice were polarized under TH0, TH1, or TH2 conditions and 
interrogated for IL-4 production.  As expected, wild-type T cells polarized under TH2 
conditions produced IL-4 upon re-challenge (Fig. 3a).  However, T cells from T-Sgk1–/– 
mice failed to produce robust amounts of IL-4.  Furthermore, loss of SGK1 resulted in 
decreased production of the TH2 cytokines IL-5 and IL-13 (Fig. 3b,c).  
 
Next, we examined the ability of T cells from T-Sgk1–/– mice to produce IFN-g and 
to be polarized to TH1 effector cells.  Without any polarizing cytokines, T cells from 
C57BL/6 mice will preferentially differentiate into TH1 cells (Fig. 3d).   CD4+ T cells from 
both wild-type and T-Sgk1–/– mice activated and cultured under non-polarizing (TH0) or TH1 
polarizing conditions led to the generation of IFN-g producing cells.  However, T cells from 
T-Sgk1–/– mice robustly expressed IFN-g even when they were differentiated under TH2 
conditions (Fig. 3d).  Thus, T cells lacking SGK1 fail to produce IL-4, IL-5, and IL-13, but 
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instead inappropriately produce IFN-g under TH2 polarizing conditions. Consistent with 
recent studies (ref. 12,13), SGK1 does not affect TH17 polarization (Supplementary Fig. 4). 
 
Next, we examined the lineage-specific transcription factors T-bet and GATA-3. As 
expected, wild-type T cells cultured under TH1 conditions expressed abundant T-bet, while 
cells cultured under TH2 conditions robustly expressed GATA-3 (Fig. 3e).  Alternatively, T 
cells derived from T-Sgk1–/– mice expressed abundant T-bet when cultured under either TH1 
or TH2 conditions.  Such cells also failed to express GATA-3 under TH2 polarizing 
conditions. Overall, these observations demonstrate a role for SGK1 in reciprocally 
regulating TH1 and TH2 differentiation.  During CD4+ T cell effector differentiation, SGK1 
activation simultaneously enhances IL-4 production and inhibits IFN-g production. 
 
SGK1 regulates TH2 differentiation by stabilizing JunB 
 
We sought to define a biochemical mechanism by which SGK1 regulates TH1 and 
TH2 differentiation. We did not observe a defect in IL-4 receptor expression or IL-4-induced 
STAT6 phosphorylation in the absence of SGK1 (data not shown). Previous studies on the 
role of SGK1 in renal epithelial cells have demonstrated that SGK1 negatively regulates the 
HECT-type E3 ligase by phosphorylation at serine 342 and serine 448 (refs. 5,10). A closely 
related homolog of NEDD4-2 is the ubiquitin ligase Itch, which has been shown to interact 
with the NEDD4 family–interacting protein 1 (Ndfip1) adapter protein to mediate 
polyubiquitination of JunB26,27.  JunB has been shown to be essential for TH2 
development26,28. We sought to determine if the defect in TH2 differentiation that we 
observed in T-Sgk1–/– mice could be in part due to increased ubiquitination and destruction 
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of JunB by NEDD4-2. As previously shown28, JunB abundance was higher in wild-type T 
cells cultured under TH2 conditions compared to those cultured under TH1 conditions (Fig. 
4a). In SGK1-deficient T cells, we observed that JunB protein abundance was decreased 
under both TH1 and TH2 polarizing conditions (Fig. 4a). These findings correlated with the 
phosphorylation status of NEDD4-2 at S342.  That is, inhibition of NEDD4-2 (as measured 
by p-NEDD4-2 S342) was greatest under TH2 conditions and decreased in the absence of 
SGK1 (Fig. 4a).   
 
We next investigated the ability of SGK1 to regulate NEDD4-2 in vivo. To this end, 
we adoptively transferred congenically marked Thy1.1+, ovalbumin (OVA)-specific CD4+ T 
cells from wild-type or T-Sgk1–/– mice into naïve hosts that were subsequently immunized 
with OVA in alum to induce a TH2 response. Similar to the in vitro results, we observed p-
NEDD4-2 S342 phosphorylation and inhibition upon stimulation of wild-type adoptively 
transferred cells (Fig. 4b). By contrast, NEDD4-2 was not phosphorylated and inhibited in 
T-Sgk1–/– adoptively transferred cells.  
Our data are consistent with the hypothesis that NEDD4-2 degrades JunB protein in 
T cells lacking SGK1 even under TH2 conditions, both in vitro and in vivo.  To further test 
this hypothesis, wild-type and T-Sgk1–/– T CD4+ cells were activated under TH2 conditions 
in the presence of the proteasome inhibitor MG132. JunB abundance was markedly 
decreased in the T cells lacking SGK1 when compared to the wild-type T cells (Fig. 4c).  
However, expression of JunB protein was restored in T-Sgk1–/– cells in the presence of 
MG132, suggesting that Jun B is expressed in T-Sgk1–/– T cells but is subsequently degraded. 
To confirm that JunB degradation was due to increased ubiquitination we 
immunoprecipitated JunB in wild-type and T-Sgk1–/– CD4+ T cells and immunoblotted for 
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ubiquitin. We found that JunB was not ubiquitinated under TH2 conditions in wild-type cells, 
but JunB ubiquitination was markedly enhanced in the absence of SGK1 (Fig. 4d).  
 
Next, we wanted to determine whether we could rescue the ability of T-Sgk1–/– CD4+ 
T cells to make IL-4 under TH2 conditions by knocking down NEDD4-2 or Ndfip using 
siRNA. Knocking down either NEDD4-2 or Ndfip led to partial rescue of IL-4 production 
in the T-Sgk1–/– TH2 polarized T cells (Fig. 4e).  Knockdown was confirmed by measuring 
the expression of NEDD4-2 and Ndfip mRNA (Supplementary Fig. 5a,b).  Additionally, 
NEDD4-2 knockdown was confirmed at the protein level, which correlated with the re-
accumulation of JunB protein (Fig. 4f). It was difficult to confirm knockdown of Ndfip at 
the protein level because the available antibodies are not robust, however knockdown of 
Ndfip also resulted in the re-accumulation of JunB protein (data not shown).  Altogether, these 
results suggest that SGK1 activation promotes TH2 differentiation in part by negatively 
regulating E3 ligases that target JunB for destruction. 
 
T-Sgk1-/- mice are resistant to Th2-mediated asthma  
 
Since we had defined the role of SGK1 in regulating the differentiation of helper T 
cells in vitro, we wanted to confirm this paradigm in an in vivo model. We chose to study the 
OVA-alum allergic asthma model because TH2 cells are involved in the early pathogenesis of 
this disease29. Therefore, we hypothesized that T-Sgk1–/– mice would be resistant to allergic 
asthma. Wild-type mice mounted a stereotypic TH2 response to this allergic stimulus, 
characterized by IL-4 in bronchoalveolar lavage (BAL) and IgE in serum. However, BAL 
and serum from T-Sgk1–/– mice contained significantly less IL-4 and IgE (Supplementary 
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Fig. 6a,b).  Alternatively, we detected OVA-specific IgG2a, characteristic of a TH1 response 
in the serum of T-Sgk1–/– mice (Supplementary Fig. 6c).  Along these lines, lung 
lymphocytes from T-Sgk1–/– mice inappropriately produced IFN-g when stimulated ex vivo 
(Supplementary Fig. 6d).  Thus in this in vivo model of TH2-mediated inflammation, loss of 
SGK1 in T cells abrogated the TH2 response and instead produced an inappropriate TH1 
response to an allergic stimulus. 
 
In light of these findings we wanted to determine if deleting SGK1 in T cells could 
prevent allergen-induced lung pathology.  To this end we challenged wild-type and T-Sgk1–/– 
mice with house dust mite (HDM) extract. Similar to our findings in the OVA-alum adjuvant 
model, we observed a marked decrease in the TH2 response of T-Sgk1–/– mice when 
challenged with HDM extract. Expression of IL-4, IL-13 and IL-5 in the lungs of T-Sgk1–/– 
mice was markedly diminished when compared to wild-type mice (Fig. 5a–c).  Likewise, we 
observed a decrease in the expression of these cytokines by CD4+ T cells in the mediastinal 
lymph nodes of T-Sgk1–/– mice (Fig. 5d–g).  We observed a significant decrease in the 
absolute number of CD4+ T cells in the lymph nodes of T-Sgk1–/– mice, however, the there 
was no significant decrease observed in the lungs and BAL fluid between wild-type and T-
Sgk1–/– mice (Supplementary Fig. 6e,f).  Consistent with our model, CD4+ T cells in the 
lungs, BAL and lymph nodes of T-Sgk1–/– mice produced significantly more IFN-g 
compared to wild-type mice (Fig. 5h,i).  Furthermore, the T-Sgk1–/– mice displayed 
decreased total IgE, in addition to decreased HDM-specific IgE and IgG1 (Fig. 5j–l).  
Finally, the lungs of the T-Sgk1–/– mice demonstrated markedly decreased goblet cell 
hyperplasia and decreased peribronchiolar and perivascular inflammation when compared to 
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the lungs of the wild-type mice (Fig. 5m–q).  Thus, loss of SGK1 in T cell protects against 
allergen-induced TH2-mediated lung disease. 
 
SGK1 negatively regulates IFN-g production via TCF-1 
 
The SGK1–NEDD4-2–Ndfip–JunB axis provides a selective mechanism as to why 
T-Sgk1–/– CD4+ T cells do not differentiate towards a TH2 phenotype.  However, it does not 
adequately explain why CD4+ T cells produce IFN-g under TH2 conditions in the absence of 
SGK1. It has previously been reported that the glycogen synthase kinase-3β (GSK-3b) is 
inhibited by the AGC kinases Akt and SGK1 (ref. 9). In turn, GSK-3b phosphorylates b-
catenin and targets this protein for degradation30,31. We observed a marked decrease in 
expression of b-catenin in T-Sgk1–/– T cells (Fig. 6a). b-catenin is critical during TH2 
differentiation because it promotes early GATA-3 expression by binding at the proximal 
promoter32. In the absence of SGK1, GSK-3b remains highly active and thus there is very 
little total b-catenin.  On the other hand, inhibiting GSK-3b in the T-Sgk1–/– T cells with 
LiCl leads to an increase in total b-catenin (Fig. 6a). 
 
The transcription factor T cell factor 1 (TCF-1) is both a downstream target of b-
catenin and a transcriptional co-activator with b-catenin31-33. Similar to T-Sgk1–/– mice, mice 
deficient in TCF-1 produce more IFN-g even under TH2 polarizing conditions32. Specifically, 
the long isoforms of TCF-1 contain an additional b-catenin binding domain, and these long 
isoforms promote TH2 polarization by increasing expression of GATA-3 and repressing 
expression of IFN-g32. We hypothesized that there would be decreased expression of the 
long form of TCF-1 in the T cells lacking SGK1.  Wild-type and T-Sgk1–/– CD4+ T cells 
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were polarized under TH1 and TH2 conditions and assayed for TCF-1 protein. We found 
that the long isoforms of TCF-1 were decreased in T-Sgk1–/– under both TH1 and TH2 
polarizing conditions, but there was no difference in expression of the short isoforms of this 
protein (Fig. 6b).  
 
To determine if SGK1 regulates TCF-1 expression at the transcriptional level, we 
designed primers that flank the b-catenin binding domain to specifically detect the long 
isoform of TCF-1. In the absence of SGK1, we observed decreased transcription of the long 
isoforms of TCF-1 at 72 h post-TCR activation, and a complete absence of transcripts at 8 
days post-stimulation (Fig. 6c). To further test this hypothesis, we sought to rescue the 
phenotype of T-Sgk1–/– CD4+ T cells by retroviral transduction with a vector encoding the 
long isoform of TCF-1 (FL-TCF-1) and a human CD8 reporter (Fig. 6d).  We sorted 
transduced cells for human CD8, then restimulated the cells and assayed for the production 
of IFN-g by intracellular staining. Wild-type T cells polarized under TH2 conditions failed to 
express IFN-g.  T cells from the T-Sgk1–/– mice, transduced with the empty vector (EV), 
expressed significant amounts of IFN-g under TH2 conditions.  Alternatively, IFN-g 
expression was mitigated when the T-Sgk1–/– T cells were transfected with FL-TCF-1 (Fig. 
6d).  These data support a model whereby under TH2 conditions SGK1 inhibits the GSK-
3b-mediated degradation of b-catenin, leading in turn to increased expression of the long 
form of TCF-1 and inhibition of IFN-g (Supplementary Fig. 7). 
 
T-Sgk1-/- mice mount robust TH1-mediated immune responses 
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The ability of SGK1 to regulate TH2 responses is in part due to its ability to 
negatively regulate IFN-g.  We wondered whether we would also see an increase in IFN-g in 
vivo under strongly polarizing TH1 conditions in the T-Sgk1–/– mice.  To this end, 
congenically marked Thy1.1+, OVA-specific wild-type and T-Sgk1–/– CD4+ T cells were 
adoptively transferred into Thy1.2+ wild-type mice that were infected intravenously with 
OVA-expressing vaccinia virus (Vac-OVA) which induces robust TH1 immune responses.  
Vaccinia infection led to a marked increase in the numbers of OVA-specific IFN-g 
producing cells from wild-type mice.  However, the TH1 response by the T cells from the 
Sgk1–/– mice demonstrated an increase in both the percentage of IFN-g producing cells and 
the amount of IFN-g produced on a per cell basis (Fig. 7a). To confirm this observation, we 
challenged wild-type and T-Sgk1–/– mice with the PR8 strain of influenza virus, which also 
promotes a strong TH1-mediated immune response.  Similar to what we observed for 
vaccinia virus, CD4+ T cells from T-Sgk1–/– mice produced more IFN-g in response to 
influenza virus infection compared to wild-type mice (Fig. 7b). 
 
To further assess the TH1 response by T-Sgk1–/– cells in vivo we employed a model of 
TH1-mediated tumor rejection, since TH1-polarized CD4+ T cells have previously been 
shown to have an important role in anti-tumor immunity34. To address this hypothesis, we 
injected wild-type and T-Sgk1–/– mice with 2 × 105 B16 melanoma cells intravenously, and 
harvested lungs 21 days later. Loss of SGK1 in T cells resulted in less than half as many lung 
tumors as compared to wild-type mice (Fig. 7c, Supplementary Fig. 8). While it is quite 
possible that the decrease in tumor burden could have been promoted by CD8+ T cells, it is 
clear that the more effective response by the T-Sgk1–/– mice was associated with an increase 
in CD4+ IFN-g producing T cells in the lungs (Fig. 7d). Next, we sought to further boost 
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tumor immunity in T-Sgk1–/– mice by vaccination. Mice were immunized with vaccinia virus 
expressing OVA seven days prior to intravenous injection of B16 melanoma cells expressing 
OVA, and survival was monitored as the primary outcome. We found that T-Sgk1–/– mice 
had significantly prolonged survival compared to wild-type mice in response to a tumor 
vaccine (Fig. 7e). Thus, the targeted deletion of SGK1 in T cells leads to enhanced tumor 





A critical task of both the adaptive and innate immune system is to integrate cues 
from the immune microenvironment and then respond appropriately.  Recently, it has 
become clear that the evolutionarily conserved serine/threonine kinase mTOR plays a 
central role in this process15.  The outcome of mTOR activation is determined by the 
regulation of selective downstream signaling pathways and substrates.  To this end, we have 
identified the AGC kinase SGK1 as an mTORC2 activated substrate that selectively 
regulates TH1 and TH2 helper T cell differentiation. T cells lacking SGK1 demonstrate a 
markedly diminished ability to differentiate into TH2 cells both in vitro and in vivo.  
Furthermore, under TH2 polarizing conditions the T-Sgk1-/- T cells inappropriately produced 
IFN-γ.  Thus, under TH2 conditions SGK1 simultaneously promotes TH2 differentiation 
while also inhibiting the production of TH1 cytokines.  Likewise, in vivo we observed 
increased IFN-γ production by the T-Sgk1-/- T cells in the setting of viral infection and anti-
tumor immunity. Of note, under TH1 polarizing conditions in vitro, the T-Sgk1-/- cells 
produced equivalent levels of IFN-γ as wild-type T cells. Perhaps this indicates that under 
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strongly polarizing conditions in vitro, the ability of SGK1 to inhibit the TH1 response is 
inconsequential.  However, in vivo, under inflammatory conditions that predominantly favor 
TH1 polarization, SGK1 signaling appears to limit the magnitude of the TH1 immune 
response.   
        
Our studies provide a mechanism by which mTOR (specifically mTORC2) 
activation regulates TH1 and TH2 differentiation.  Recently, it has been reported that SGK1 
plays a role in promoting the stability of pathogenic TH17 cells12. Notably, in this study, as in 
ours, TH17 differentiation was similar in both wild-type and T-Sgk1-/- T cells.  However, it 
was shown that SGK1 plays a role in controlling the expression of the IL-23 receptor. As a 
result, T cells lacking SGK1 respond poorly to IL-23 and T-Sgk1-/- mice are resistant to the 
development of experimental autoimmune encephalitis (EAE).  Furthermore, it was shown 
that an increase in the extracellular concentration of sodium leads to increased IL-23-
mediated TH17 differentiation and that this effect was abrogated in T-Sgk1-/- T cells.  This 
report and another link these findings to the ability of increased dietary salt to exacerbate 
EAE12,13. 
 
       Previous studies on the role of SGK1 in the kidney provided clues as to how this AGC 
kinase may be functioning in T cells11. In order to reclaim sodium in the urine, SGK1 
prevents degradation of sodium channels by phosphorylating and inhibiting the NEDD4-2 
E3 ubiquitin ligase5,6.   Similarly, we found that SGK1 promoted TH2 differentiation by 
phosphorylating and inhibiting NEDD4-2, thus preventing degradation of JunB. These 
findings are consistent with previous reports that mice lacking Ndfip or Itch display a hyper-
TH2 phenotype26,27. In these studies loss of Ndfip or Itch led to accumulation of JunB and 
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increased expression of IL-4. Overall, our studies serve to strengthen the link between 
mTOR-SGK1 and the regulation of cellular differentiation and function by E3-ligases.  Just 
as these connections have been shown to be important in T cells and renal epithelial cells, 
we propose that these pathways will prove to be important for a diversity of cellular 
functions. 
 
       Our findings identify SGK1 as a potential target for the treatment of TH2-mediated 
autoimmune and allergic diseases, such as asthma.  Currently, non-specific 
immunosuppressive agents such as steroids play an important role in the treatment of acute 
asthma flares as well as in preventing recurrences35-37. Our data suggest that the selective 
inhibition of SGK1 might represent an immunomodulatory approach to treating and 
preventing the sequelae of asthma and other allergic diseases without globally inhibiting the 
immune system.  Interestingly, small molecule inhibitors of SGK1 have already been 
developed38,39. Additionally, inhibiting SGK1 may be of therapeutic value in terms of 
enhancing TH1-mediated immune responses, for example, in the setting of viral infections or 
as an adjunct to tumor immunotherapy.  That is, while an asthmatic might take an SGK1 
inhibitor to prevent the development of TH2-mediated inflammation, the same small 
molecule inhibitor might be given to a patient in the midst of receiving cancer 







Figure 1. SGK1 is activated downstream of TCR signaling in an mTOR-dependent 
manner.  (a) Immunoblot (IB) of naïve lymphocytes from 5C.C7 mice that were rested for 
1 h prior to stimulation with anti-CD3 and anti-CD28. Cells were lysed, and the activity of 
SGK1 was measured by blotting for phosphorylated NDRG1 (p-T346). The activity of 
mTORC2 was measured by blotting for phosphorylated Akt (p-S473). Total protein and 
actin are included as loading controls. (b) IB of CD4+ T cells isolated from 5C.C7 mice, as 
described in a, and stimulated for 3 h in the presence of polarizing cytokines. Cells were 
lysed and immunoblotted for SGK1 and Akt activity. (c) IB of naïve 5C.C7 lymphocytes, as 
described above. Where indicated, the mTOR kinase inhibitor PP242 (1 mM) was added to 
the cells upon stimulation. Total protein and actin are included as loading controls. Data are 
representative of 3-5 independent experiments (a-c). 
 
Figure 2. SGK1 is activated downstream of mTORC2 in T cells. (a) IB of wild-type 
(WT), T-Rictor–/–, and T-Sgk1–/– CD4+ T cells that were stimulated as in Fig. 1a. Cells were 
lysed and the activity of Akt and SGK1 was measured as above. Total protein and actin are 
included as loading controls. (b-e) Flow cytometric phenotyping data compiled from 
multiple mice (n = 6) showing percentages of B220+, CD3+, CD4+ and CD8+ cells from WT 
and T-Sgk1–/– spleen (b-c) and lymph nodes (d-e).  CD4+ and CD8+ subsets in (c) and (e) 
were gated on CD3+. (f) CD4+ T cells were isolated from WT or T-Sgk1–/– mice, stained 
with carboxyfluorescein succinimidyl ester (CFSE), and stimulated with irradiated syngeneic 
APCs and 1 mg/mL anti-CD3 for 24, 48, 72 or 96 h. Unstimulated (US) cells are shown as a 
control. (g) Naïve CD4+ T cells were isolated and stimulated overnight with 0.3, 1.0, or 3.0 
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mg/ml plate-bound anti-CD3 and 2.0 mg/ml soluble anti-CD28. Supernatants were 
harvested to determine IL-2 production by ELISA. ND = not detectable. Data are 
representative of 3 independent experiments (a-g) and samples were analyzed in triplicate in 
each experiment (g). Statistical significance determined by Student’s t-test, NS=No 
Significance, error bars s.e.m.  
 
Figure 3. SGK1 reciprocally regulates TH1 and TH2 differentiation downstream of 
mTORC2. (a) IL-4 production of activated CD4+ T cells by ELISA. Naïve CD4+ T cells 
from WT and T-Sgk1–/– mice were isolated based on expression of CD44 and CD62L. Cells 
were stimulated with irradiated autologous APCs under TH0, TH1 or TH2 polarizing 
conditions as indicated in the Methods. (b,c) As in a, but supernatants were assayed for IL-
5 (b) or IL-13 (c) production by ELISA. (Statistical significance calculated by ANOVA, *P < 
0.001, error bars s.e.m.) (d) IFN-g production of activated CD4+ T cells by intracellular 
staining. Cells were stimulated and rested as in a prior to activation with overnight plate-
bound anti-CD3 and soluble anti-CD28 in the presence of Golgi plug. Numbers represent 
percentages of cells in each quadrant. (e) IB of activated CD4+ T cells for lineage-specific 
transcription factors. Cells were stimulated with plate-bound anti-CD3 and anti-CD28 for 48 
h then rested for 5 days in IL-2. Live cells were harvested, lysed and immunoblotted for T-
bet and GATA-3. Actin is included as a loading control. Right, flow cytometric data showing 
intracellular staining for the transcription factors T-bet and GATA-3. Cells were fixed and 
permeabilised to determine expression of T-bet and GATA-3 by flow cytometry. Mean 
Fluorescence Intensity (MFI) is displayed on each respective flow plot. Data are 
representative of 4 independent experiments (a-e) and samples were analyzed in triplicate in 
each experiment (a-c).  
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Figure 4. SGK1 promotes Th2 differentiation by negatively regulating NEDD4-2. (a) 
IB of cell extracts from WT and T-Sgk1–/– CD4+ T cells that were stimulated in vitro under 
either TH1 or TH2 polarizing conditions. Cells were lysed and blotted for the expression of 
JunB and the activity of the E3 ligase NEDD4-2 (by measuring p-S342). Total NEDD4-2 
and actin are included as loading controls. ImageJ software was used to calculate band 
density from 3 independent experiments, and band density was normalized to loading 
controls and to WT TH1 conditions. (Statistical significance calculated by ANOVA, **P < 
0.001, error bars s.e.m.) (b) Intracellular staining of Thy1.1+ adoptively transferred cells for 
phosphorylated NEDD4-2. OT-II CD4+ T cells bearing the Thy1.1 congenic marker were 
adoptively transferred into WT Thy1.2+ recipients immunized with OVA adsorbed onto 
alum to induce a Th2 immune response. Spleens were harvested on day 4, restimulated with 
OVA Class II peptide, and intracellular staining was performed for phosphorylated 
NEDD4-2.  Plots depict MFI of indicated samples. (Statistical significance calculated by 
ANOVA, *P =0.0183. (c) IB of cell extracts of WT and T-Sgk1–/– treated with MG132. Cells 
were polarized under TH2 conditions as in a, but with the addition of the proteasome 
inhibitor MG132 during the final 2 h of stimulation. Lysates were blotted for JunB, and actin 
is included as a loading control. (d) Immunoprecipitates (IPs) of JunB from WT and T-Sgk1–
/– CD4+ T cells polarized with IL-4 and treated with MG132. As in c, but lysates were 
subject to IP with JunB antibody.  IPs were blotted for ubiquitin and immunoprecipitated 
JunB is included as a loading control. (e) IL-4 production of CD4+ T cells transfected with 
siRNA targeting NEDD4-2 or Ndfip. A non-specific pool of siRNA (scrambled, Scr) was 
used as a control. Cells were stimulated under TH2 polarizing conditions for 48 h prior to 
transfection with siRNA then expanded in IL-2 for 5 d. Cells were restimulated overnight 
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with anti-CD3 and anti-CD28 and supernatants were harvested to determine cytokine 
production. (f) CD4+ T cells from WT or T-Sgk1–/– mice were treated as in (e) then lysed for 
immunoblot to show knockdown of NEDD4-2 and rescue of JunB protein. (Data not 
shown for Ndfip.) (Statistical significance calculated by ANOVA, **P < 0.001, error bars 
s.e.m.) Data are representative of 3 independent experiments (a–d), 4 independent 
experiments (e) or 2 independent experiments (f).  
 
Figure 5. Loss of SGK1 activity in CD4+ T cells mitigates TH2-mediated disease in an 
allergen induced asthma model. (a–c) IL-4, IL-13 and IL-5 production from lung 
lymphocytes from mice that had been sensitized intraperitoneally and re-challenged 
intranasally on days 14 and 21 with HDM extract to induce allergic airway inflammation. 
Lung lymphocytes were stimulated for 3 days ex vivo with HDM extract, and supernatants 
were harvested and analyzed by ELISA for cytokine production. (d–g) IL-4, IL-13 and IL-5 
production from mediastinal lymph nodes from mice that had been immunized as in a–c. 
Lymphocytes were stimulated ex vivo with PMA and ionomycin for 4 h, then fixed, 
permeabilised and analyzed by intracellular staining and flow cytometry for cytokine 
production. (h) Lymphocytes were harvested from lung parenchyma or BAL, stimulated ex 
vivo with PMA and ionomycin for 4 h, and analyzed for production of IFN-g by intracellular 
staining and flow cytometry as described above. (i) As in h, but lymphocytes were harvested 
from mediastinal lymph nodes. (j–l) Total IgE (j), HDM specific IgE (k), and HDM specific 
IgG1 (l) in serum from mice that were sensitized and rechallenged with HDM extract as 
described above. Antibody titers were extrapolated from a standard curve (if available) or 
absorbance is shown for a dilution of serum for which all samples were in the range of the 
assay. (m,n) Representative lung sections after periodic acid-Schiff (PAS) (m) or 
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hematoxylin and eosin (H&E) (n) staining for saline control (mock) and HDM-treated mice. 
Pathologic changes in WT mice include goblet cell hyperplasia (m) and perivascular and 
peribronchiolar inflammation (n). Images from HDM treated mice are shown at 10x (top, 
middle rows) and at 20x magnification (bottom row). (o-p) Histologic scoring data of PAS+ 
cells in large bronchioles (o) and small bronchioles (p) from HDM-treated mice. (q) 
Histologic scoring data of perivascular and peribronchiolar inflammation as seen in H&E 
stained lung sections as described above. Data are representative of 3 independent 
experiments (a-i), 4 independent experiments (j-l) or 2 independent experiments (m-q), n = 
5–11 mice per group. (Statistical significance determined by Student’s t-test (a-q), **** P < 
0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, error bars s.e.m.) 
 
Figure 6. SGK1 negatively regulates TH1 differentiation via the long isoform of TCF-
1. (a) IB of cell extracts from WT and T-Sgk1–/– CD4+ T cells stimulated under TH2 
polarizing conditions and treated overnight with 25 mM LiCl. Lysates were blotted for p-b-
catenin (S33/47/T41) and total b-catenin. Total GSK-3b is included as a loading control. (b) 
IB of cell extracts from WT and T-Sgk1–/– CD4+ T cells that were stimulated in vitro under 
either TH1 or TH2 polarizing conditions. Cells were lysed and blotted for TCF-1. Actin is 
included as a loading control. Two exposures are shown to appreciate differences in long 
and short isoforms of TCF-1, short exposure (top), long exposure (bottom). (c) Expression 
of long isoform of TCF-1 in activated CD4+ T cells at early and late time points during 
differentiation. CD4+ T cells were purified from WT and T-Sgk1–/– mice by magnetic 
separation, stimulated with anti-CD3 anti-CD28 magnetic beads for 2 d in TH1 or TH2 
conditions then rested in IL-2 for 6 d. Fold induction of long isoform of TCF-1 normalized 
18S rRNA and to WT TH1 polarizing conditions at 72 h and 8 days post stimulation, as 
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analyzed by quantitative polymerase chain reaction. (d) Flow cytometric analysis of CD4+ T 
cells polarized under TH2 conditions and transduced to overexpress the long isoform of 
TCF-1 (FL-TCF-1) with an MSCV retrovirus containing a human CD8 marker. Following 
transduction, cells were rested then sorted for human CD8 surface expression. Cells were 
restimulated and analyzed for production of IFN-γ by intracellular staining. Cells were gated 
on low, intermediate, and high expression of human CD8. Histogram overlays of human 
CD8 high cells are shown to emphasize differences in IFN-γ production among cells with 
similar multiplicity of infection. Data are representative of 3 independent experiments (a-c) 
or 4 independent experiments (d), and samples were analyzed in triplicate in each 
experiment (c). (Statistical significance calculated by ANOVA, P<0.001, error bars s.e.m.)  
 
Figure 7. Loss of SGK1 enhances TH1-mediated viral and tumor immunity. (a) IFN-g 
production from adoptively transferred OT-II cells that were restimulated ex vivo with PMA 
and ionomycin. OT-II cells were adoptively transferred into mice that had been 
simultaneously immunized intravenously with 1 × 106 pfu VAC-OVA. Positive gates for 
IFN-g were set using a no stimulation control such that <1.0% of cells were allowed in the 
positive gate. Plots gated on adoptively transferred cells (left) and bar graph depicts MFI 
(right). n = 10 mice per group. (b) IFN-g production from lung lymphocytes of mice 
infected intranasally with the PR8 strain of influenza. On day 8, lung lymphocytes were 
harvested and stimulated for 4 h ex vivo with PMA and ionomycin then fixed, permeabilized 
and analyzed by intracellular staining and flow cytometry for IFN-g production. (c) Number 
of B16 melanoma lung metastases. WT and T-Sgk1–/– mice were injected intravenously with 
2 × 105 B16 melanoma cells, and lungs were harvested 21 days later. The number of lung 
metastases were counted and expressed as mean + s.e.m. (d) As in b, lung lymphocytes were 
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harvested and stimulated for 4 hours ex vivo with PMA and ionomycin and analyzed by 
intracellular staining for production of IFN-g by CD4+ T cells. (e) Kaplan-Meier analysis of 
WT and T-Sgk1–/– mice vaccinated with 1 × 106 pfu VAC-OVA 7 days prior to challenge 
with 2 × 105 B16 melanoma cells expressing OVA (B16-OVA). T-Sgk1–/– mice have 
prolonged survival (P<0.0001, n = 5–7 mice per group). Data are representative of 2–3 
independent experiments, n = 5–15 mice per group. Statistical significance determined by 
Student’s t-test (a–d) or Log-rank (Mantel Cox) survival analysis (e), ****P < 0.0001, ***P < 
0.001, **P < 0.01, *P < 0.05, error bars s.e.m.  
 
Supplementary Figure Legends 
Supplementary Figure 1. Sgk1 mRNA is expressed in CD4+ and CD8+ T cells and is 
upregulated in response to cytokines. (a) CD4+ and CD8+ T cells were isolated from wild-
type and T-Sgk1-/- mice by magnetic separation, and RNA was isolated. Sgk1 mRNA levels 
were determined by polymerase chain reaction using the following excision primers: forward 
primer 5-CTCAGTCTCTTTTGGGCTCTTT-3 and the reverse primer 5-
TTTCTTCTTCAGGATGGCTTTC-3, as described in the Methods. GAPDH is included 
as a loading control. Data is representative of 3 independent experiments. (b) CD4+ T cells 
were isolated from 5C.C7 mice using magnetic separation, and cells were stimulated with 
anti-CD3 and anti-CD28 for 1 hour under polarizing conditions. RNA was isolated and 
reverse transcribed into cDNA to measure expression of Sgk1 by RT-PCR. Expression is 
normalized to the unstimulated control and to 18s rRNA expression. 
Supplementary Figure 2. mTORC2 is required for activation of SGK1. (a) Model 
depicting downstream targets of mTORC2. Activation of mTORC2 leads to 
phosphorylation of Akt (p-S473) and SGK1 (p-S422). Activation of SGK1 leads to 
 50 
phosphorylation of its downstream target NDRG1 (p-T346). (b) ImageJ software was used 
to calculate band density from 3 independent experiments shown in Fig. 2a, and band 
density was normalized to loading controls and to WT unstimulated (US) conditions. (c) 
Flow cytometric analysis of CD4+ T cells isolated from WT, T-Rictor-/-, and T-Sgk1-/- mice 
and stimulated with anti-CD3 and anti-CD28 for 1,3, or 6 hours. Cells were permeabilised 
with methanol and interrogated for phosphorylation of Akt (S473) using flow cytometry. 
Numbers in upper right corner of each plot indicate mean fluorescent index (MFI) of p-Akt 
or total Akt. Below, MFI of p-Akt from flow cytometry plots above were normalized to the 
MFI of total Akt. Data are representative of 3 independent experiments (a-c), statistical 
significance calculated by ANOVA, ns=no significance, error bars s.e.m.). 
Supplementary Figure 3. Characterization of lymphocyte development and maturation of 
T-Sgk1-/- mice. (a) Flow cytometric phenotyping data compiled from multiple mice (n=6) of 
double negative (CD4-CD8-), double positive (CD4+CD8+), or single positive (CD4+ or 
CD8+) thymocytes, (b,c) absolute numbers of B220+, CD3+, CD4+, and CD8+ cells in the 
spleen and lymph nodes, (d-g) expression of CD44 and CD62L on both CD4+ and CD8+ 
subsets in the spleen and lymph nodes, (h) expression of Treg phenotypic markers (CD3+ 
CD4+ CD25+ FoxP3+) in spleen and lymph nodes. Data are compiled from 6 mice and are 
representative of 3 independent experiments. Statistical significance determined by Student’s 
t-test, NS=No Significance, *P<0.05 **P<0.01, error bars s.e.m. 
Supplementary Figure 4. SGK1 is not required for TH17 differentiation in vitro. 
Intracellular staining of CD4+ T cells that were polarized for 48 hours under TH0 or TH17 
(IL-6 and TGF-β) conditions, then rested and restimulated as in Fig. 3D. Data is 
representative of 3 independent experiments. 
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Supplementary Figure 5. Knockdown of NEDD4-2 and Ndfip by siRNA. Quantitative 
PCR analysis of NEDD4-2 (a) and Ndfip (b) mRNA in CD4+ T cells from WT and T-
Sgk1-/- mice. RNA was harvested from cells 24 hours after transfection with siRNA for 
analysis by real time PCR. Gene expression is normalized to 18s rRNA and to the WT 
scrambled control. Data is representative of two independent experiments, and samples were 
analyzed in triplicate for each experiment. Statistical significance calculated by ANOVA, 
*P<0.001, error bars s.e.m.) 
Supplementary Figure 6. Decreased Th2 mediated immunity in vivo in T-Sgk1-/- mice in 
asthma models.  (a) IL-4 production in bronchoalveolar lavage (BAL) harvested from mice 
that had been sensitized with OVA in alum i.p., then rechallenged with intranasal OVA on 
days 15, 16, and 17, followed by sacrifice on day 18. Lungs were lavaged with PBS and 
analyzed by ELISA. (b) Total IgE in serum. (c) OVA-specific IgG2a in serum. (d) IFN-γ 
production by lung lymphocytes, as measured by intracellular staining and flow cytometry. 
As in A, lung lymphocytes were harvested from diseased mice and stimulated for 4 hours ex 
vivo with PMA and ionomycin. (e) Analysis of CD4+ lymphocytes found in the lungs and 
mediastinal lymph nodes of mice that were sensitized and challenged with HDM extract as 
described in Fig 5. Graph depicts absolute number of CD4+ T cells recovered from each 
compartment. (f) BAL was analyzed by cytospin and Diff-quick staining for the presence of 
lymphocytes in WT and T-Sgk1-/- mice that were sensitized and challenged with HDM 
extract as described in Fig 5. Data are representative of 3 independent experiments, and 
n=5-11 mice per group, *P<0.05, **P<0.01, ***P<0.001. (Statistical significance calculated 
by ANOVA (d) or Student’s t test, error bars s.e.m.) 
Supplementary Figure 7. Model depicting regulation of TCF-1 by SGK1. In WT T cells, 
activation of mTORC2 downstream of TCR signaling results in activation of SGK1. In turn, 
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SGK1 phosphorylates and inhibits GSK-3β. When GSK-3β is inactive, its target β-catenin 
cannot be degraded. Active β-catenin cooperates with the long isoforms of TCF-1 to 
promote transcription of TCF-1, which inhibits expression of IFN-γ. In T-Sgk1-/- cells, 
GSK-3β is active and thus targets β-catenin for destruction. Loss of β-catenin leads to 
decreased expression of TCF-1 long isoforms, and thus increased expression of IFN-γ. 
Supplementary Figure 8. Reduced melanoma tumor burden in T-Sgk1-/- mice. 
Representative images from one of 3 independent experiments showing reduced melanoma 
tumor burden in the lungs of T-Sgk1–/– mice as compared to WT mice. 
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CHAPTER 3: SGK1 controls CD8+ memory differentiation by regulating Foxo1 
 
Introduction 
During an acute viral infection, antigen-specific CD8+ T cells expand rapidly, 
undergoing one cell division every 4 hours1. Two distinct subsets of CD8+ T cells arise 
during the course of an anti-viral immune response: cytotoxic effector cells and memory 
cells. The pool of CD8+ T cells at the height of the effector response can be divided into at 
least 2 subsets based on expression of the IL-7 receptor (IL-7R/CD127) and killer cell 
lectin-like receptor subfamily G, member 1 (KLRG1). Short-lived effector cells are CD127LO 
and KLRG1HI, whereas memory precursor cells are CD127HI and KLRG1LO 2-4. Effector and 
memory cells display also differences in their ability to survive, which underscores their 
unique roles in the immune response. Cytotoxic effector cells can proliferate rapidly to kill 
virally infected targets, but most of these cells undergo apoptosis during the contraction 
phase of the immune response. By contrast, memory cells divide slowly but have enhanced 
longevity compared to effector cells5. If rechallenged by a virus expressing the same antigen, 
memory cells can expand rapidly in a burst of proliferation that characterizes the secondary 
immune response6.  
 
Once a pathogen is cleared, memory cells are maintained in an antigen-independent, 
cytokine-dependent manner2,7. Memory cells are exquisitely sensitive to and dependent upon 
homeostatic cytokines such as IL-7 and IL-15 for their survival and self-renewal2,8. Thus, 
memory cells are characterized by high surface expression of the IL-7 and IL-15 cytokine 
receptors (IL-7R/CD127 and IL-15R/CD215)9. The basal rate of proliferation that is 
required for maintenance of memory cells is referred to as homeostatic proliferation10,11. 
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Expression of CD127 alone, however, is not sufficient to enforce memory differentiation12. 
Rather, memory cells require a distinct transcriptional program to deliver instructive signals 
for proliferation and survival.  
 
In addition to a distinct surface receptor phenotype, memory cells are also 
distinguished by their expression of the T-box transcription factor eomesodermin 
(EOMES)13. The expression of EOMES seems to be reciprocally regulated with Tbet, 
another T-Box transcription factor that predominates in effector cells14,15. Although it is 
expressed in effector cells albeit at low levels, EOMES is necessary for memory 
differentiation. Loss of EOMES in CD8+ T cells results in an inability to generate memory 
cells that display homeostatic proliferation and homing to lymph nodes and bone marrow13.  
It has recently been appreciated that the ratio of Tbet and EOMES is in part regulated by 
mTOR16. Thus, a model is emerging whereby mTOR regulates the balance of effector versus 
memory potential of CD8+ T cells via its regulation of downstream transcriptional 
networks. 
 
Much like mTOR controls the differentiation of helper CD4+ T cells, there is new 
evidence to suggest that mTOR controls the effector to memory transition in CD8+ T 
cells16-18.  Several studies have shown that inhibition of mTOR can lead to enhanced memory 
T cell differentiation16,17,19. Based on the divergent metabolic demands of effector and 
memory cells this is not surprising.  However, it suggests that rapamycin, initially described 
as an immunosuppressive agent, may also be employed to enhance CD8+ memory 
generation.  Indeed, in a mouse model of Lymphocytic Choriomeningitis Virus (LCMV) 
rapamycin was shown to increase the number of virus-specific CD8+ T cells by promoting 
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survival of memory T cells during the contraction phase of the immune response17. The 
observed decrease in attrition was due to upregulation of the anti-apoptotic factor Bcl-217.  
Furthermore, it has been shown that rapamycin can promote CD8+ memory cell generation 
by inhibiting T-bet activation and enhancing EOMES activity16.  In this model, treating mice 
with rapamycin during vaccination led to enhanced anti-tumor immunity. These studies 
suggest that mTOR is a critical regulator of downstream transcriptional networks that drive 
CD8+ T cell differentiation during an immune response. However, it is unclear what is the 
precise role of TORC1 versus TORC2 in regulating effector and memory differentiation. 
 
Because of the emerging role of mTOR in regulating CD8 T cell responses, we 
hypothesized that SGK1 might also be an important regulator of effector and memory 
differentiation.  Unpublished work from our laboratory has shown that loss of TORC2 
activity (using T-Rictor-/- mice) is not necessary for effector differentiation.  There is some 
evidence to suggest, however, that loss of TORC2 results in enhanced memory 
differentiation, characterized by decreased attrition of cells during the contraction phase of 
the immune response. Since SGK1 is a critical node downstream of mTORC2, we 
hypothesized that SGK1 might be responsible for the enhanced memory phenotype that we 
observe in T-Rictor-/- mice. To this end, we utilized our T-SGK1-/- mice to study the role of 




Mice. Mice were kept in accordance with guidelines of the Johns Hopkins University 
Institutional Animal Care and Use Committee. Mice with loxP-flanked SGK1 alleles were 
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generated in the Fejes-Tóth laboratory, and mice with loxP-flanked Rictor alleles were 
provided by M. Magnuson. C57BL/6, Cd4-Cre, RAG2-/- and OT-I mice were obtained 
from Jackson Laboratories and bred to Thy-1.1 backgrounds. 5C.C7 mice were from 
Taconic Farms.  
 
T cell stimulation. CD8+ T cells were purified by negative selection using a CD8+ 
isolation kit and MACS Cell Separation (Miltenyi Biotec). For immunoblot analysis of 
mTOR substrates, T cells were stimulated with mouse T activator magnetic Dynabeads 
coated with antiCD3/antiCD28 (Life technologies) for 1 or 3 hours. For coculture 
experiments, T cells were stimulated with activator beads for 48 hours, then expanded in IL-
7 (Peprotech). 
 
Vaccinia model. Mice were immunized with 1e6 pfu VAC-OVA by either retroorbital 
injection or intraperitoneal injection. For adoptive transfer experiments, 1e6 naïve CD8+ T 
cells specific for the OVA Class I epitope (OVA 257 - 264) congenically marked with Thy1.1 
were transferred intravenously to Thy1.2 C57/BL6 recipients by retroorbital injection.  
 
Homeostatic proliferation model. 1e6 naïve CD8+ T cells congenically marked with 
Thy1.1 were labeled with 5.0 uM CFSE and transferred intravenously to RAG2-/- recipients 
via retroorbital injection. Spleens were harvested on day 5 and analyzed by flow cytometry 
for CFSE dilution and expression of CD127. 
 
Chromatin immunoprecipitation. Chromatin immunoprecipitation assays were done 
using the MAGnify chromatin immunoprecipitation kit (Applied Biosystems) according to 
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the manufacturer’s instructions. Briefly, 10e6 Thy1.1+ adoptively transferred and sorted cells 
were fixed with 1% formaldehyde in PBS for 10 min at 25°C. Following fixation, cells were 
lysed for 5 minutes at 4 °C. Chromatin was sheared by sonication using a Biorupter UCD 
200 on high power for 16 cycles of 30 seconds on, 30 seconds off. Sheared chomatin lysates 
were centrifuged, diluted, and divided into two equal fractions for incubation overnight at 4 
°C with 5.0 μg of rabbit anti-mouse Foxo1 antibody (Cell Signaling, 2880) or rabbit IgG 
bound to magnetic beads. Immunoprecipitated chromatin was washed and eluted from the 
beads, and reverse crosslinked. After treatment with proteinase K, DNA was isolated using 
magnetic beads and resuspended in Tris-EDTA buffer. Immunoprecipitates and input 
fraction were analyzed in triplicate by qPCR using SYBR green PCR Master Mix (Applied 
Biosystems), and the following primers:  
CD127 forward: 5′- ACCTCATCAGCCTTTCATGG -3′,  
CD127 reverse: 5’-ATCCCCTGAGCAAACTAGCA-3’ 
Eomesodermin forward 5’- CAAAGAGGGCTCGTTGAGAG -3’  
Eomesodermin reverse 5’- CCTAATTCGCGTGCTTCTTT -3’ 
 
Antibodies and reagents. The following antibodies for flow cytometry were from BD 
Biosciences: CD8, CD90.1/Thy1.1, CD90.2/Thy1.2, and CD62L (559772). The following 
antibodies for flow cytometry were from eBioscience: CD127 (17-1271), CD122 (12-1221), 
and eomesodermin (51-4875). 
 
Class I iTAG tetramers bearing the OVA epitope (SIINFEKL) were from Beckman Coulter. 
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The following antibodies for immunoblotting were from Cell Signaling Technologies: 
pNDRG1 T346 (3217), pAkt S473 (4060), pS6K1 T389 (9204), pS6 S235/236 (4858), total 
S6 (2217), total S6 (2211), pFoxo1 S256 (9461), total Foxo1, clone C29H4 (2880), pSTAT5 
Y694, clone C11C5 (9359), and total STAT5, clone 3H7 (9358).  
 
Cytokines were from Peprotech, CFSE was from Invitrogen, and pp242 was from 
ChemDea. 
 
Intracellular staining.  Cells were stained for surface antigens, fixed and made permeable 
with the eBioscience Fixation/Permeabilization kit, then stained for transcription factors. 
Annexin V antibodies and binding buffer were from BD Biosciences. 
 
Flow Cytometric Analysis. Flow cytometric data was acquired using a BD FACS Calibur, 
and analyzed using FlowJo7.6 (Tree Star Inc, Ashland, OR). Gates were determined by using 
unstimulated controls or isotype controls where appropriate. 
 
Cells were sorted using a BD FACS Aria at the Flow Cytometry Core at the Sidney Kimmel 
Comprehensive Cancer Center, JHMI. 
 
Immunoblot analysis. For immunoblot analysis, T cells were harvested by centrifugation 
and resuspended in ice-cold lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerolphosphate (glycerol-2-phosphate), 1 mM sodium orthovanadate, 1 mM PMSF, 1× 
protease inhibitors (Roche, Basel, Switzerland)) and lysed at 4 °C for 30 min. Lysates were 
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cleared of debris by high speed centrifugation. Equal protein mass from each condition was 
mixed with 4× LDS buffer (Invitrogen, Carlsbad, CA) and boiled for 10 min. Lysates were 
then loaded into NuPAGE gels (4-12% Bis–Tris gels, Invitrogen) and run at 150 V for 
90 min. Protein was transferred to polyvinylidene fluoride (PVDF) membranes with transfer 
buffer (1× NuPAGE Transfer Buffer (Invitrogen) with 20% methanol) at 30 V for 90 min. 
Membranes were blocked in 5% nonfat dry milk (NFDM) for 60 min, washed briefly with 
Tris-buffered saline + 0.1% Tween-20 (TBST) and probed with primary antibody in 4% 
NFDM in TBST overnight at 4°C. Membranes were washed with TBST three times for 
10 min and probed with secondary antibody conjugated to HRP in NFDM. Membranes 
were washed 2 times in TBST for 5 min, and then once in Tris-buffered saline once for 
5 min. Enhanced chemiluminescent plus substrate (GE Healthcare) was used to detect HRP-
labeled antibodies. Blots were developed using a Biospectrum Multispectrum Imaging 
System and images were acquired and analyzed using VisionWorks, LS Image Acquisition 
and Analysis software (UVP, Upland, CA). 
 
Real-time qPCR. RNA was isolated and reverse transcribed into cDNA using the 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) according to the 
manufacturer’s protocol. Primer and probe sets used to detect CD127, eomesodermin, and 
18S rRNA were from Applied Biosystems. Taqman Universal Master Mix II, no UNG was 
used for qPCR. RT qPCR was performed using a Step One Plus Real Time PCR System 
(Applied Biosystems).  
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Statistical analysis. Prism version 5.0 (GraphPad Software) was used to perform statistical 
analyses, including unpaired Student’s t-test and 2-way Analysis of Variance (ANOVA). A p 





SGK1 is activated downstream of mTORC2 in CD8 T cells.  
 
We have previously shown that SGK1 is activated downstream of TCR signaling in 
CD4 T cells (Chapter 2), so we sought to determine whether SGK1 was similarly regulated 
in CD8 T cells. Naïve RAG2-/- OT1 CD8 T cells were stimulated with anti-CD3 and anti-
CD28 to measure the phosphorylation of the SGK1 substrate N-myc downregulated gene 1 
(NDRG1). As we observed in CD8 T cells, activity of SGK1 as measured by pNDRG1 
T346 increased upon TCR stimulation and was inhibited by the dual mTOR kinase inhibitor 
pp242, in a similar manner to the mTORC1 and mTORC2 substrates, pS6 S235/236 and 
pAkt S473, respectively (Fig 1A).   
 
We have previously shown that SGK1 is activated in an mTORC2 dependent 
manner in CD4 T cells (Chapter 2). To determine whether SGK1 was downstream of 
mTORC2 in CD8 T cells, T-SGK1-/- CD8 T cells were activated in vitro and the 
phosphorylation of mTORC2 substrates was measured by immunoblot. T-Rictor-/- mice 
completely lack mTORC2 activity and exhibit loss of Akt activity and SGK1 activity (Fig 
1B), suggesting that both Akt and SGK1 are downstream of mTORC2. In T-SGK1-/- mice, 
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however, selective loss of pNDRG1 T346 was observed, but Akt S473 phosphorylation 
remained intact. Therefore, we have placed SGK1 downstream of mTORC2 in a pathway 
that is parallel to Akt in CD8+ T cells.  
 
SGK1 regulates expression of CD127 and survival in response to homeostatic 
cytokines. 
 
CD8+ T cells from T-SGK1-/- cultured in IL-7 in vitro proliferate to a similar degree 
compared to Wt cells (Supplementary Figure 1). However, we wanted to determine if Wt 
and T-SGK1-/- CD8+ T cells would demonstrate differences in survival, particularly in the 
context of limiting concentrations of homeostatic cytokines and competition for growth 
factors. To address this question, Wt (Thy1.2) and T-SGK1-/- (Thy1.1) CD8 T cells were 
cocultured in vitro in limiting concentrations of IL7 following 48 hours of stimulation. T-
SGK1-/- CD8 T cells demonstrated enhanced survival, particularly when the concentration 
of homeostatic cytokine was limiting (1.0 pg/ml IL-7) (Fig 1C). Accordingly, T-SGK1-/- 
cells constitutively upregulate CD127 when forced to compete with Wt cells for IL-7 (Fig 
1D). This enhanced expression of CD127 was correlated with no change in proliferation, but 
this effect was correlated with enhanced survival of T-SGK1-/- CD8+ T cells that was most 
pronounced at the lowest concentration of IL7 (Fig 1C). Of note, there were no differences 
in the ability of naïve CD8+ T cells from T-SGK1-/- mice to signal through CD127, as 
measured by phosphorylation of STAT5 in response to IL-7 (Supplementary Figure 2). 
 
Loss of SGK1 results in aberrant expression of memory markers on effector T cells. 
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Next, we sought to determine if SGK1 regulated survival and expression of CD127 
in vivo in CD8+ T cells in a model of vaccination. Wt and T-SGK1-/- mice were immunized 
with vaccinia virus expressing the model antigen ovalbumin (VAC-OVA) and the fate of 
antigen specific T cells was followed over the course of the immune response. Consistent 
with our in vitro data, Wt and T-SGK1-/- OVA specific T cells proliferated similarly during 
the effector phase of the immune response (Day 0-7) (Fig 2A). These results suggest that 
SGK1 is not required for effector differentiation. Furthermore, there was no difference in 
the ability of T-SGK1-/- effector cells to kill antigen-loaded targets in an in vivo CTL assay 
(Supplementary Figure 3).  
 
Although SGK1 is not required for effector differentiation, our data suggest that loss 
of SGK1 may enhance memory differentiation. In the VAC-OVA model, loss of SGK1 lead 
to decreased attrition of OVA-specific T cells during the contraction phase of the immune 
response (Day 8-32), suggesting that SGK1 represses memory differentiation (Fig 2A). 
Upon antigen recognition, Wt CD8 T cells downregulate the memory marker CD127 and 
upregulate KLRG1, a marker of effector cells. Similar to what we observed in vitro, OVA-
specific T-SGK1-/- cells were unable to downregulate CD127 and expressed high levels of 
this memory marker at the height of the effector response on day 7.  
 
Since SGK1 is deleted in both CD4 and CD8 subsets in T-SGK1-/- mice, we 
performed an adoptive transfer of OT1 Thy1.1 CD8 T cells from T-SGK1-/- mice into Wt 
recipients, who were simultaneously immunized with VAC-OVA. Similar to our results on 
the endogenous response to VAC-OVA, adoptively transferred cells from T-SGK1-/- mice 
proliferated similarly to Wt on day 6. There was no difference in the number of Thy1.1+ 
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adoptively transferred cells from Wt and T-SGK1-/- donors (Fig 2B). However, adoptively 
transferred effector cells from T-SGK1-/- mice displayed aberrant expression of CD127 (Fig 
2B).  Furthermore, loss of SGK1 also lead to aberrant expression of the memory associated 
transcription factor EOMES (Fig 2B). 
 
SGK1 is not required for homeostatic proliferation 
 
Because loss of SGK1 leads to upregulation of CD127, we hypothesized that CD8+ 
T cells from T-SGK1-/- mice would demonstrate enhanced homeostatic proliferation. To 
address this question, CD8+ Thy1.1+ T cells from Wt or T-SGK1-/- mice that had been 
labeled with CFSE were adoptively transferred into RAG2-/- Thy1.2+ recipients. 
Unexpectedly, there was no difference in the number of cell divisions that occurred in 
response to lymphopenia when comparing Wt and T-SGK1-/- cells (Fig 2C). (Note: this 
observation may be due to lack of competition for IL-7 since this experiment was not 
performed as a co-adoptive transfer.) Interestingly, there was marked upregulation of CD127 
on the adoptively transferred cells from T-SGK1-/- mice, whereas CD127 was 
downregulated on the Wt adoptively transferred cells. Lymphopenia in the setting of RAG 
deficiency leads to high serum concentrations of IL-7, which should lead to downregulation 
of CD12720. These results suggest that expression of CD127 remains (inappropriately) 
constitutively high in the absence of SGK1 signaling.  
  
SGK1 regulates CD127 and Eomesodermin expression via phosphorylation of Foxo1. 
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Next, we sought to determine the mechanism by which SGK1 was regulating 
expression of CD127 and EOMES. Both CD127 and EOMES are transcriptional targets of 
the forkhead box transcription factor Foxo1, which has been shown to promote survival and 
memory differentiation in CD8+ T cells21,22. Upon T cell activation, the Foxo transcription 
factors are phosphorylated, resulting in their translocation from the nucleus to the 
cytoplasm. Phosphorylation and sequestration of Foxo in the cytoplasm ensures that these 
transcription factors are held in an inactive state by association with 14-3-3 scaffolding 
proteins23-25. 
 
It has previously been reported in HEK293 cells that SGK1 directly phosphorylates 
Foxo126. In naïve CD8 T cells, Foxo1 is dephosphorylated and thus active in the nucleus21,27. 
Not surprisingly, there was no difference in phosphorylation of Foxo1 in naïve CD8+ T 
cells from Wt and T-SGK1-/- mice (Fig 3A). Furthermore, there were no differences in the 
expression of several Foxo1 target genes (CD122, CD127, and CD62L) in naïve cells from 
Wt versus T-SGK1-/- mice (Supplementary Figure 4). These results are consistent with 
previously published results that Foxo1 is active in naïve T cells, where it promotes survival 
and homeostatic turnover21,27. 
 
In effector CD8+ T cells, Foxo1 is phosphorylated and thus sequestered in the 
cytoplasm where is it kept inactive. We predicted that loss of SGK1 would result in loss of 
Foxo1 phosphorylation, and inappropriately high Foxo1 activity in effector CD8+ T cells. 
To this end, OT1 Thy1.1+ CD8+T cells from Wt or T-SGK1-/- were adoptively transferred 
into naïve recipients who were simultaneously immunized with VAC-OVA. On Day 6 post 
infection, the adoptively transferred cells were sorted and assayed for the activity of Foxo1 
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by immunoblot. On day 6 post infection, phosphorylation of Foxo1 increased in Wt 
adoptively transferred cells, which correlated with decreased Foxo1 activity (Fig 3A). By 
contrast, Foxo1 was not phosphorylated in adoptively transferred cells from T-SGK1-/- 
mice.  
 
We hypothesized that the increased expression of CD127 and EOMES that were 
observed in vivo in T-SGK1-/- was due to increased activity of Foxo1. Since these genes are 
transcriptional targets of Foxo121,22, mRNA expression of CD127 and EOMES was 
measured in day 6 adoptively transferred cells. Loss of SGK1 lead to marked upregulation of 
CD127 and EOMES transcripts in T-SGK1-/- cells compared to Wt (Fig 3B).  To confirm 
that increased expression of CD127 and EOMES was due to Foxo1, we performed 
chromatin immunoprecipitation of Foxo1 from Day 6 adoptively transferred cells. CHiP 
revealed binding of Foxo1 to enhancer elements in the CD127 and EOMES promoters in T-
SGK1-/- mice, but not Wt mice (Fig 3C, D). These data are consistent with previously 
published reports of Foxo1 binding to enhancer elements in the promoters of these genes in 
naïve and memory cells. In the absence of SGK1, however, Foxo1 promotes transcription of 
these genes by constitutively binding to enhancer elements, even in effector CD8 T cells 





A model is emerging whereby mTOR regulates AGC kinases (such as SGK1 and 
Akt), which in turn regulate a transcriptional program that leads to either effector or memory 
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differentiation (Fig 4). At the center of the transcriptional network that drives memory 
differentiation is the forkhead box (FOXO) family of transcription factors. In resting or 
naïve T cells where mTOR/SGK1/Akt are not active, the FOXO proteins reside in the 
nucleus where they promote expression of downstream targets. Upon T cell activation, 
however, SGK1 and Akt phosphorylate the FOXOs, resulting in their translocation from the 
nucleus to the cytoplasm, where they are held in an inactive state by association with 14-3-3 
scaffolding proteins23-25. SGK1 has previously been shown to phosphorylate Foxo1 in 
CCL39 fibroblasts and HEK 293T cells26. For the first time, our data establish a role for 
SGK1 in regulating Foxo1 in CD8 T cells.  
 
The subcellular localization of the FOXO transcription factors is controlled by 
phosphorylation at several sites. In studies on HEK293 cells, both Akt and SGK1 can 
phosphorylate Foxo1, but these kinases have preferences for different sites26. For example, 
Akt seems to favor phosphorylation at serine 253, while SGK1 favors serine 31526. On the 
other hand, both Akt and SGK1 readily phosphorylate threonine 32 in Foxo126. Transfection 
of HEK293 cells with kinase inactive mutants of SGK1 or Akt resulted in inappropriate 
retention of Foxo1 in the nucleus upon growth factor stimulation26. By contrast, 
constitutively active Akt or SGK1 resulted in inappropriate retention of Foxo1 in the 
cytoplasm upon growth factor withdrawal, leading to apoptosis26. These findings suggest that 
SGK1 and Akt have partially overlapping but nonredundant roles in controlling subcellular 
localization and thus Foxo1 activity.  Thus, the regulation of Foxo1 by both Akt and SGK1 
is critical to promoting survival upon growth factor withdrawal, such as that which occurs 
during the contraction phase of the immune response.  
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Recently, several reports have suggested that Foxo1 plays a critical role in regulating 
CD8 memory cell differentiation downstream of Akt22,28. Strong TCR signaling in the 
context of IL-12 promotes activation of mTOR, which in turn activates Akt and drives 
differentiation of terminal effector cells22. Sustained Akt activity results in enhanced effector 
differentiation28. However, decreased expression of CD127, EOMES, and the anti-apoptotic 
transcription factor Bcl2 results in an inability to mount a memory response for long-term 
protective immunity28. By contrast, inhibition of Akt results in enhanced memory 
differentiation28. Mechanistically, decreased Akt activity leads to an increase in Foxo1 
activity, which allows Foxo1 to bind to the enhancer regions of CD127 and EOMES to 
promote expression of these memory markers22. Thus, Akt and SGK1 are critical in fine-
tuning the balance of effector versus memory differentiation in CD8 T cells. Taken together, 
our data supports a model whereby mTORC2 regulates downstream AGC kinases to control 




Figure 1. SGK1 regulates survival in response to homeostatic cytokines in  CD8 T 
cells. (A) Immunoblot (IB) of naïve lymphocytes from 5C.C7 mice that were serum starved 
for 1 hour prior to stimulation with anti-CD3 and anti-CD28. Cells were lysed, and the 
activity of SGK1 was measured by blotting for phosphorylated NDRG1 (T346). The activity 
of mTORC1 and mTORC2 was measured by blotting for phosphorylated S6 (S235/236) 
activity downstream of TORC1, and for Akt activity downstream of TORC2 (S473). Total 
protein levels and actin are included as loading controls. (B) IB of WT, T-Rictor-/-, and T-
SGK1-/- CD4+ T cells that were stimulated as in A. Cells were lysed and the activity of 
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mTORC2 and SGK1 was measured as above. Actin is included as a loading control. (C) 
Flow cytometry plots of WT and T-SGK1-/- CD8 T cells cocultured in vitro. CD8 T cells 
from WT (Thy1.2) and T-SGK1-/- (Thy1.1) were stained with 0.5 uM CFSE and stimulated 
in vitro with anti-CD3 and anti-CD28 for 48 hours, then expanded in limiting concentrations 
of IL-7 (10.0 pg/ml, 2.0 pg/ml, or 1.0 pg/ml). At 96 hours, proliferation was measured by 
CFSE dilution, and death was measured by Annexin V staining. (D) As in 1C, cultures were 
stained and analyzed by flow cytometry for the ratio of Thy1.1 to Thy1.2 positive cells and 
expression of CD127. Where indicated, values represent the percent of cells in each 
quadrant, mean fluorescent index (MFI) of CD127 expression.  
 
Figure 2. Loss of SGK1 results in aberrant expression of CD127 on CD8 effector T 
cells in response to Vaccinia virus. (A) Percent of antigen-specific CD8 T cells during an 
immune response to VAC-OVA. WT and T-SGK1-/- mice were immunized with 1e6 pfu 
vaccina virus expressing the model antigen OVA (VAC-OVA) by intraperitoneal (i.p.) 
injection on day 0. The number of OVA-specific CD8 T cells was monitored at interval 
timepoints over 30 days post infection by serial cheek bleed. Graph depicts the percentage of 
antigen specific T cells as meausured by flow cytometry using MHC I tetramers loaded with 
the OVA epitope SIINFEKL (OVA 257-264). Histogram depicts expression of CD127 on 
tetramer positive cells on day 7. (B) Response of adoptively transferred OT1 cells to VAC-
OVA. 1e6 OT1 Thy1.1 cells from WT or T-SGK1-/- mice were adoptively transferred to 
WT recipients, who were simultaneously immunized with 1e6 pfu VAC-OVA i.p. Graphs 
depict the percentage of Thy1.1 positive cells among CD8+ splenocytes as measured by flow 
cytometry on Day 6 post adoptive transfer & immunization. Expression of CD127 and 
eomesodermin in adoptively transferred cells was measured by flow cytometry, and plotted 
 105 
as MFI. (C) Number of cell divisions measured by CFSE dilution in a homeostatic 
proliferation model. 1e6 Thy1.1+ CD8+ T cells were CFSE labeled and adoptively 
transferred into RAG2-/- recipients. Splenocytes were harvested on day 7 post-adoptive 
transfer and analyzed by flow cytometry for dilution of CFSE and expression of CD127. 
 
Figure 3. SGK1 controls expression of CD127 and Eomesodermin by regulating 
Foxo1. (A) IB of naïve and adoptively transferred cells sorted from splenocytes of mice 
immunized with VAC-OVA. WT Thy1.2 mice were immunized with 1e6 pfu VAC-OVA 
and simultaneously received 1e6 OT1 Thy1.1 T cells. Spleenocytes were harvested 6 days 
later and sorted based on a CD8+Thy1.1+. Sorted cells were lysed and immunoblotted, and 
naïve OT1 cells are included as a control. Total Foxo1 protein and actin are shown as 
loading controls. (B) mRNA expression of CD127 and eomesodermin in adoptively 
transferred cells. Mice were immunized and received adoptive transfer of OT1 Thy1.1 T 
cells as in A. Cells were sorted and RNA was harvested and reverse transcribed. Graphs 
depict quantitative PCR results for expression of CD127 and eomesodermin, relative to 18s 
rRNA control. (C) Foxo binding sites in the CD127 and eomesodermin promoters. 
Conserved Foxo responsive elements are located at -3.5 kb and -150 bp in the CD127 and 
eomesodermin promoters, respectively. Arrows depict primer binding sites for chromatin 
immunoprecipitation in D. (D) Chromatin immunoprecipitation of Foxo1 at the CD127 and 
eomesodermin promoters. CD8+Thy1.1+ cells were sorted as in A, and lysates were subject 
to shearing and chromatin immunoprecipitation with Foxo1 antibody. qPCR was used to 
measure abundance of CD127 and eomesodermin promoter sequences that were bound to 
Foxo1 or IgG control. Graphs depict fold enrichment of Foxo1 at the sites indicated on the 
CD127 and eomesodermin promoters, normalized to IgG control and input control. 
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Figure 4. Model depicting regulation of CD127 and eomesodermin by Foxo1 and 
SGK1.  In effector CD8 T cells, high mTOR activity leads to phosphorylation and activation 
of SGK1. In turn, SGK1 phosphorylates Foxo1 which leads to its exclusion from the 
nucleus and sequestration in the cytoplasm by binding 14-3-3 proteins. In memory CD8 T 
cells, low mTOR activity is not sufficient to phosphorylate and activate SGK1. As a result, 
the Foxo transcription factors are not phosphorylated and held in the cytoplasm, but rather 
translocate to the nucleus where they bind to Foxo responsive elements in target genes such 




Supplementary Figure 1. Proliferation of WT and T-SGK1-/- CD8 T cells in vitro. 
CD8 T cells from WT (Thy1.2) and T-SGK1-/- (Thy1.1) were labeled with 0.5 uM CFSE 
and stimulated in vitro with anti-CD3 and anti-CD28 magnetic stimulator beads for 48 
hours, then expanded in limiting concentrations of IL-7 (10.0 pg/ml, 2.0 pg/ml, or 1.0 
pg/ml). 
 
Supplementary Figure 2. IB of CD8 T cells for phosphorylated STAT5 in response to 
a dose curve of IL-7. CD8+ T cells were isolated from WT and T-SGK1-/- (KO) mice and 
cultured with IL-7 (1.0 ng/ml, 0.1 ng/ml, or 0.01 ng/ml) for 30 minutes. Cells were lysed 




Supplementary Figure 3. In vivo CTL killing assay. WT and T-SGK1-/- mice were 
immunized with VAC-OVA, then challenged on day 6 with efluor labeled targets that were 
pulsed with OVA peptide or no peptide as a control. Histograms depict the percentages of 
cells among the no peptide control (efluor low) or OVA pulsed targets (efluor high) at 4 and 
6 hours post challenge from representative mice.  
 
Supplementary Figure 4. Expression of Foxo target genes on naïve CD8 T cells. 
Splenocytes were harvested from WT and T-SGK1-/- mice and analyzed by flow cytometry 
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CHAPTER 4: Discussion and Future Directions 
 
Summary of Findings in CD4+ T cells 
 
In summary, these results demonstrate a previously unappreciated role for SGK1 in 
both CD4+ and CD8+ T cells. SGK1 is a key mediator downstream of TORC2 that is 
involved in influencing T cell differentiation in both lineages. In CD4+ T cells, loss of 
SGK1 leads to a constitutive IFNγ-producing, Th1 phenotype, while Th2 differentiation is 
impaired. Mechanistically, loss of SGK1 leads to increased ubiquitination and destruction of 
JunB via the E3 ligase NEDD4-2. This results in decreased IL-4 production and impaired 
Th2 differentiation in T-SGK1-/- mice. Furthermore, loss of SGK1 leads to a decrease in 
expression of the long isoforms of TCF-1, resulting in enhanced IFNγ production and a 
constitutive Th1 phenotype. 
 
Our mechanistic studies on the role of SGK1 in CD4+ T cells have been 
strengthened by our in vivo observations in various disease models using T-SGK1-/- mice. We 
have shown that these mice are resistant to Th2-mediated disease, such as allergic asthma, 
since CD4+ T cells from these mice inappropriately produce IFN-γ and thus mount a 
protective Th1 response. In a melanoma model, we have shown that enhanced IFN-γ 
production in T-SGK1-/- mice leads to robust rejection of tumors and prolonged survival.  
Altogether, these results suggest that inhibition of SGK1 may be a useful target for 
immunomodulatory therapies that seek to enhance a Th1 immune response. 
 
Summary of Findings in CD8+ T cells 
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In CD8+ T cells, we have shown that loss of SGK1 may lead to an enhanced 
memory phenotype. In a model of infection with vaccinia virus expressing OVA, we have 
shown that loss of SGK1 results in inappropriate expression of memory markers, such as 
CD127 and EOMES, on effector cells. Decreased attrition of antigen-specific T cells in T-
SGK1-/- mice during the contraction phase of the immune response suggests that these 
mice may have an enhanced memory phenotype.  
 
We hypothesized that the mechanism of decreased attrition in T-SGK1-/- mice might 
be due to increased activity of the FOXO transcription factors. It has been shown that 
FOXO transcription factors lead to increased expression of the IL-7 receptor (CD127), 
which is associated with survival of long-lived memory cells due to their ability to proliferate 
in response to homeostatic cytokines like IL-71,2. Foxo1 has also been shown to bind to 
enhancer regions of the EOMES promoter. Indeed, antigen-specific CD8+ T cells from T-
SGK1-/- mice show increased expression of CD127 and EOMES, even at the height of the 
effector phase of the viral immune response. 
 
Future Directions and Applications 
 
The mTOR pathway is an ideal target for new therapies that specifically and potently 
inhibit a particular arm of the T effector response. Our work has previously established that 
mTORC1 is necessary for Th1 and Th17 development, while TORC2 is necessary for Th2 
development3. This dissertation advances our understanding of how mTOR reciprocally 
regulates Th1 and Th2 differentiation via SGK1. By defining the downstream components 
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of this signaling pathway, we have identified targets that can be manipulated to more 
precisely control T cell differentiation.  
 
Immunomodulatory drugs that are currently in clinical use are non-selective and 
globally suppress T cell responses. For example, rapamycin and mTOR kinase inhibitors 
globally inhibit differentiation of effector T cells and promote regulatory T cell development. 
However, complete immunosuppression is not always desirable, particularly in autoimmune 
disease. In some disease settings, such as asthma for example, a particular subset of T 
effector cell is responsible for disease pathogenesis. Atopic/allergic asthma seems to be 
driven by a Th2 response, but Th1 and Th17 subsets are largely not involved in the immune 
response4. Thus, it is desirable to specifically inhibit autoreactive Th2 cells in asthma, while 
leaving other helper T cell subsets untouched, in order to preserve immunity to foreign 
pathogens. Therefore, SGK1 may be a particularly promising target in treating 
allergic/atopic asthma, where Th2 subsets are primarily involved in promoting disease 
pathogenesis. 
 
It has been well established that CD4+ and CD8+ effector and memory T cells are 
necessary for developing long-lasting immunity against tumors5,6 Since loss of SGK1 lead to 
robust rejection of tumors, these results suggest that SGK1 may be a good target for anti-
tumor immunomodulatory therapies. Furthermore, since loss of SGK1 in CD8+ T cells 
leads to enhanced memory differentiation, inhibiting SGK1 in T cells may also promote 
lasting tumor immunity. Finally, inhibition of SGK1 may also have an anti-proliferative 
effect on cancer cells directly, as several groups have reported that TORC2 signaling is 
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upregulated in certain cancers and tumor cells lines7-9. We propose that inhibitors of SGK1 
may be used as chemotherapy or as adjuvant therapy to boost the efficacy of tumor vaccines.  
 
In WT mice that fail to reject their tumors, we predict that tumor infiltrating 
lymphocytes become tolerant and fail to proliferate, resulting in few tumor antigen-specific 
T cells that make little IFNγ. However, we hypothesize that loss of SGK1 in T cells will lead 
to a robust CD4+ and CD8+ effector response characterized by a high numbers of antigen-
specific, IFNγ-secreting T cells. To further enhance the anti-tumor immune response in T-
SGK1-/- mice, we propose that combining deletion of SGK1 with inhibition of PD-1 will 
lead to complete tumor regression. In WT mice that fail to reject their tumors, we 
hypothesize that the anti-tumor immune response is ineffective because Teff become 
exhausted. Tumors express high levels of ligands for the PD-1 receptor, which is a marker of 
exhausted T cells. Even though T-SGK1-/- mice may mount a robust effector T cell 
response to tumor antigens, we cannot rule out the possibility that IFNγ-producing Teff 
become exhausted and thus ineffectual within the tumor microenvironment. This 
phenomenon could explain our observation that T-SGK1-/- mice have reduced tumor 
burden, but they cannot completely eliminate their tumors. Therefore, one future direction 
of this work might be to study the effects of loss SGK1 on tumor growth in combination 
with an antibody that inhibits PD-1. Monoclonal antibodies targeting PD-1 are commercially 
available and are currently being tested in clinical trials for treating melanoma, where they 
have demonstrated efficacy even in patients with advanced metastatic disease10. 
 
Our findings on the role of SGK1 in promoting anti-tumor immunity provide a 
therapeutic rationale for how inhibitors of SGK1 might be used in combination with 
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chemotherapy or other immunomodulatory agents like anti-PD1 in the treatment of 
neoplastic diseases. Notably, several small molecule inhibitors of SGK1 have been 
developed. One compound (GSK650394) is commercially available, and we plan to 
synthesize another compound that was recently published11. In future work, we would like to 




Figure 1. Summary of Findings. SGK1 represents a central node in a signaling complex 
downstream of mTORC2 that regulates CD4+ and CD8+ T cell differentiation. In CD4+ T 
cells, SGK1 phosphorylates and inhibits the E3 ligase NEDD4-2, resulting in decreased 
destruction of JunB. SGK1 also phosphorylates and inhibits GSK-3β, which phosphorylates 
and targets β-catenin for destruction. Β-catenin upregulates transcription of its 
transcriptional co-activator, TCF-1, which represses IFN-γ. In CD8+ T cells, SGK1 
phosphorylates Foxo1, which results in sequestration of this transcription factor in the 
cytoplasm. When Foxo1 is dephosphorylated, it translocates to the nucleus to bind to the 
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